1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds

Abstract

The present invention relates to substituted 1,4-dihydro-4-oxoquinolines having antiviral activity. The substituents are present at positions 1, 2 and at least one of 5-8 positions of the quinoline ring.

Description

FIELD OF THE INVENTION

[0001] This invetion related to a group of 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds and the use of said compounds as an antiviral agent.

BACKGROUND OF THE INVENTION

[0002] The enteroviruses, rhinoviruses and hepatovirus are three groups within the family Picornaviridae which cause a wide range of human viral disease. The enterovirus group comprises 67 distinct serotypes, including 3 strains of poliovirus, 23 group A and 6 group B coxsackieviruses, 31 echoviruses, and 4 the newer numbered enteroviruses. Enteroviruses cause a broader range disease syndrome including “summer flu”, upper respiratory illness, acute hemorrhagic conjunctivitis, hand, foot and mouth disease, myocarditis, aseptic meningitis, and poliomyelitis. Hepatitis A virus (HAV) was provisionally classified as enterovirus type 72. However, later studies have demonstrated several characteristics that distinguish HAV from other picornaviruses. It is concluded that HAV is a unique member of the family Picornaviridae, resulting in its classification into a new genus, Hepatovirus. HAV is a common cause of both sporadic and epidemic acute hepatitis in humans, produces substantial morbidity. Among the agents of viral hepatitis, HAV is most prevalent, but it is clinically less important than the hepatitis B and C virus. The clinical manifestations of HAV infection in humans can vary greatly, ranging from asymptomatic infection, commonly seen in young children, to fulminant hepatitis, which in some cases can result in death.

[0003] Human rhinovirus (HRV), which include over 100 different serotypes are the most important etiological agents of the common cold. Infection of the upper respiratory tract by members of the HRV group represents perhaps the most common viral affliction of humans, accounting for some 40 to 50% of common colds. Although HRV-induced upper respiratory illnesses often mild and self-limiting, severe disease can occur in subjects predisposed to respiratory problems, such as asthmatics. From an economic standpoint, rhinovirus infections of humans represent a significant health problem in terms of numbers of physicians' office visits, costs associated with symptomatic treatments and days lost from work and school.

[0004] Thus, infections with more than 200 different serotypes of picornavirus cause significant morbidity and mortality. The vast serotypic diversity of these viruses precludes development of vaccines for the control of human infection by these virus groups except for poliovirus and hepatitis A virus. Currently, there is no specific antiviral therapy to treat or prevent picornavirus infections.

[0005] Rotaviruses are the single most important etiologic agents of severe diarrheal illness of infant and young children world-wide. Although diarrheal diseases are one of the most common illness of infant and young children throughout the world, they assume a special significance in less developed countries, where they constitute a major cauase of mortality among the young. Rotavirus infection produces a spectrum of responses that vary from subclinical infection to mild diarrhea to a severe and occasionally fatal dehydrating illness. At present, neither a vaccine nor specific antiviral medication has been discovered for human rotavirus infections.

[0006] We have found that a group of 1,4-dihydro-4-oxoquinoline derivatives have a potent antiviral activity against picornaviruses and rotaviruses.

SUMMARY OF THE INVENTION

[0007] The present invention provides a 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compound of Formula I; 1

[0008] wherein each R1 is a member independently selected from the group consisting of alkyl, cycloalkyl, phenyl, alkoxy, cycloalkyloxy, phenoxy, methylenedioxy, trifluoromethyl, halogen, OH, NO2, NH2, mono- or dialkylamino, pyrrolidino, piperidino, piperazino, 4-hydroxypiperazino, 4-methylpiperazino, 4-acetylpiperazino, morpholino, pyridyl, pyridyloxy, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiomorpholino, dialkylaminoalkylamino, N-alkylaminoalkyl-N-alkylamino, N-hydroxyalkyl-N-alkylamino, dialkylaminoalkoxy, acetoxy, hydroxycarbonyloxy, alkoxycarbonyloxy, hydroxycarbonylmethoxy and alkoxycarbonylmethoxy, and n is 1,2 or 3

[0009] wherein R2 is a member selected from the group consisting of alkyl, pyridyl, pyrazinyl, furyl, N-alkylpyrrolyl, thiazolyl, thienyl which may be optionally substituted with alkyl or halogen, and phenyl which may be optionally substituted with up to two substituents independently selected from the group consisting of halogen, OH, alkyl, alkoxy, trifluorometlyl and acetoxy;

[0010] wherein R3 is a member selected from the group consisting of hydrogen, alkyl, phenyl, alkoxy, alkoxycarbonyl, alkylsulfonyl, CN and acetyl; or

[0011] if R2 is a phenyl group optionally substituted with halo, alkyl or alkoxy groups, R3 may represent a bridging group between the 3rd position of the quinoline ring and said phenyl group at a position next to the ring carbon atom at which said phenyl group is directly connected to the quinoline ring, said bridging group being selected from the group consisting of methylene, carbonyl, hydroxyiminomethylidene, alkoxyiminomethylidene, alkanoylaminomethylidene, aminomethylidene, hydroxymethylidene, 1-hydroxy-1,1-alkylidene, α-hydroxybenzylidene, 1-alkoxy-1,1-alkylidene, α-alkoxybenzylidene, 1,2-ethylidene and 1,3-propylidene; or

[0012] if R2 is 2-thienyl, 4- or 5-alkyl-2-thienyl or N-alkylpyrrol-3-yl, R3 may represent methylene bridge between the 3rd position of the quinoline ring and said thienyl group at the 3rd position or said pyrrolyl group at the 2nd position, and

[0013] wherein R4 is a member selected from the group consisting of alkyl, alkenyl, benzyl and phenyl optionally substituted with halo, alkyl or alkoxy.

[0014] In a preferred embodiment, the compound of the present invention has Formula I-a: 2

[0015] wherein R2′ is phenyl or substituted phenyl having up to two substituents independly selected from the group consisting of halo, OH, alkyl, alkoxy, trifluoromethyl and acetoxy;

[0016] R3′ is hydrogen, alkyl, phenyl, alkoxy, alkoxycarbonyl, alkyl-sulfonyl, CN or acetyl; and

[0017] R1, R4 and n are as defined above.

[0018] In another embodiment, the compound of the present invention has Formula I-b: 3

[0019] wherein R2″ is alkyl, pyridyl, pyrazinyl, furyl, N-alkylpyrrolyl, thienyl, substituted thienyl having up to two halo- or alkyl substituents, or thiazolyl; and

[0020] R1, R3′, R4 and n are as defined above.

[0021] In other embodiments, if R2 is pheny or substituted phenyl in the formula I, R3 may be a bridge forming a fused ring system including the quinoline and benzene rings.

[0022] When the bridge is formed of a single carbon atom, the compound of the present invention is a derivative of 5,6-dihydro-11H-indeno[1,2-b]quinoline of Formula I-c: 4

[0023] wherein R5 is a member independly selected from the group consisting of hydrogen, halo, alkyl and alkoxy;

[0024] R6 and R7 together with the carbon atom to which they are attached represent a bridge selected from the group consisting of methylene, carbonyl, hydroxyiminomethylidene, alkoxyiminomethylidene, alkanoylaminomethylidene, aminomethylidene, hydroxymethylidene, 1-hydroxy-1,1-alkylidene, α-hydroxybenzylidene, 1-alkoxy-1,1-alkylidene and α-alkoxybenzylidene;

[0025] m is 1 or 2; and

[0026] R1, R4 and n are as defined above.

[0027] When the bridge is 1,2-ethylidene, the compound of the present invention is a derivative of 6,12-dihydrobenzo[c]-acridine of Formula I-d: 5

[0028] wherein R1, R4, R5, n and m are as defined above.

[0029] When the bridge is 1,3-propylidene, the compound of the present invention is a derivative of 5,6,7,13-tetrahydro-8H-benzo[6,7]cyclohepta[1,2-b]quinoline of Formula I-e; 6

[0030] wherein R1, R4, R5, n and m are as defined above.

[0031] In further embodiments, if R2 is thienyl, 4- or 5-alkyl-2-thienyl or N-alkyl-pyrrol-3-yl, R3 may be a methylene bridge forming a fused ring system including the quinoline ring and the thiophene or pyrrole ring. Thus, the compounds of the present invention include a derivative of thieno[3′, 2′:4,5]-cyclopenta[1,2-b]quinoline-5-one of Formula I-f: 7

[0032] wherein R8 is hydrogen or alkyl; and

[0033] R1, R4 and n are as defined above.

[0034] Also included in the compounds of the present invention is a derivative of pyrrolo[3′,2′:4,5]cyclopenta[1,2-b]quinoline-5-one of Formula I-g: 8

[0035] wherein R9 is alkyl, and R1, R4 and n are as define.

[0036] The compounds of the present invention also include a pharmaceutically acceptable acid addition salt or quaternary ammonium salt thereof.

[0037] The invention also relates to a pharmaceutical composition comprising a compound of Formula I above and a pharmaceutically acceptable carrier. The pharmaceutical composition of the invention is useful in the prophylaxis and the treatment of viral infections of Picornavirus and human rotavirus.

DETAILED DESCRIPTION OF THE INVENTION

[0038] Throughout the specification and claims, several terms are difined as follows.

[0039] Alkyl including the alkyl moiety of alkoxy refers to a straight chain or branched alkyl of up to 8, preferably 6 carbon atoms.

[0040] Alkenyl refers to an alkenyl of 2-6, preferably 3-4 carbon atoms.

[0041] Cycloalkyl refers to a cycloalkyl of 5-7 carbon atoms, preferably cyclohexyl.

[0042] Halogen refers to fluorine, chlorine or bromine.

[0043] The compounds of Formula I may be synthesized by use of known chemical reactions and procedures starting from appropriately substituted aniline II.

[0044] Generally, the synthesis of the compounds of Formula I follows either Method A or Method B. In Method A, substituted anilines II are reacted with 2-benzoylalkanoic acid ethyl ester III in the presence of polyphosphoric acid to give 2-phenyl-4-oxoquinoline derivatives (IV) followed by the reaction with R4I in the presence of sodium hydride. Method A is applicable to the synthesis of the compounds of Formula I-a. Scheme I. Method A 9

[0045] In Method B, the compounds of Formula I are prepared from substituted anilines II via N-substituted isatoic anhydrides VIII.

[0046] The intermediate VIII, in turn, may be synthesized by two methods as shown in Scheme II below. Substituted anilines II are reacted with chloral hydrate and hydroxylamine to yield nitrosoacetanilide V. Cyclization of V into substituted isatins VI followed by introduction of R 4 at position 1 yields N-substituted isatins VII. N-substituted isatoic anhydrides VIII are obtained by treating VII with m-chloroperbenzoic acid(m-CPBA). Alternatively, N-substituted isatoic anhydride VIII may be prepared by reacting isatins VI with m-CPBA to produce N-unsubstituted isatoic anhydrides IX followed by introduction of R4 at position 1. N-substituted isatins VII may also be prepared by reacting N-substituted anilines XII with oxalyl chloride followed by aluminum chloride. N-substituted anilines XII, in turn, may be prepared by acetylating substituted anilines II, reacting the resulting acetanilides X with an alkylating agent to introduce R4 followed by deacetylation of the N-substituted acetanilides XI. 10

[0047] N-Substituted isatoic anhydrides VIII are used in Method B for the synthesis of the compounds of Formula I by the reaction with an appropriate ketone in the presence of n-butyl lithium and tetramethylethylenediamine (TMEDA) or in the presence of sodium hydride.

[0048] In Method B1 for the preparation of the compounds of Formula I-a, the ketone compound may be represented by the formula: R2′C(O)CH2R3′, wherein R2′ is phenyl or substituted phenyl having one or two substituents independently selected from the group consisting of halo, OH, alkyl, alkoxy, trifluoromethyl and acetoxy; and R3′ is hydrogen, alkyl, phenyl, alkoxy, alkoxycarbonyl, alkylsulfonyl, CN or acetyl. The reaction involved in Method B1 is shown in Scheme III. 11

[0049] Similarly, Method B2 for the preparation of the compounds I-b, a ketone of the formula: R2″C(O)CH2R3′, wherein R2″ is alkyl, pyridyl, pyrazinyl, furyl, N-alkylpyrrolyl, thienyl, substituted thienyl having up to two halo- or alkyl substituent or thiazolyl; and R3′ is as defined above is used. The reaction involved in Method B2 is shown in Scheme IV. 12

[0050] The compounds of Formula I-c wherein both R6 and R7 are hydrogen as well as the compounds of Formula I-d and Formula I-e are prepared by Method B3 shown in Scheme V. 13

[0051] Specifically, the oxo compound XIII are 1-indanones for the compounds of Formula I-c(x=1, R6, R7=H), 1-tetralones for the compounds Formula I-d (x=2) and 1-oxobenzosuberones (x=3), respectively.

[0052] The compounds of Formula I-c wherein R6 and R7 together represent oxo may be prepared by reacting the isatoic anhydride VIII with a 1,3-indandione XIV to obtain 5,10-dihydro-11H-indeno[1,2-b]quinolin-10, 11-dione compounds XV as shown in Scheme VI. 14

[0053] The 11-oxo compounds XV may be further manipulated using known methodoloy to obtain the compounds of Formula I-c wherein R6 and R7 are other than oxo. Reaction of 11-oxo compounds XV with hydroxylamine gives a corresponding oxime. Reaction of oxime with an alkylating agent in the presence of sodium hydride gives a 11-alkoxyimino compound. The oxime further gives a 11-alkanoylamino compound by acylation with an acylating agent such as acetyl anhydride in a reducing atomosphere. Saponification of 11-alkanoylamino compound leads to 11-amino compound.

[0054] The 11-oxo compounds XV may be converted into a 11-hydroxy compound by the reaction with sodium borohydride. Reaction of 11-oxo compounds XV with alkyl- or phenyl magnesium halide leads to a 11-hydroxy-11-alkyl or phenyl devivative. The hydroxy group at position 11 may further be alkylated in the presence of sodium hydride to give a 11-alkoxy-11-alkyl or phenyl derivative. The hydroxy group at position 11 may be removed by the reaction with sodium iodide and trimethylsilyl chloride to give 11-alkyl or phenyl derivative.

[0055] Finally, the compounds of Formula I-f and Formula I-g may be prepared by Method B4 as shown in Scheme VII. The compounds of Formula I-f are prepared by the reaction of isatoic anhydride VIII with 4,5-dihydro-6H-cyclopenta[b]-thiophen-6-one XVI in the presence of n-BuLi and TMEDA. Reaction of isatoic anhydride VIII with 1-methyl-5,6-dihydro-4H-cyclopenta[b]pyrrol-4-one XVII in the presence of n-BuLi and TMEDA gives the compounds of Formula I-g. 15

EXAMPLES

[0056] The following examples are given for illustrative purposes only.

[0057] Part A. 16

Example 1

1-Ethyl-2-phenyl-3-methyl-6-isopropyl-1,4-dihydro-4-oxoquinoline(Compound A37)

[0058] Step 1. 2-phenyl-3-methyl-6-isopropyl-1,4-dihydro-4-oxoquinoline

[0059] To polyphosphoric acid (1.5 g) heated to 160° C. were added dropwise a solution of 4-isopropylaniline(0.5 g, 3.6 mmol) and ethyl 2-benzoylpropionate (1.52 g, 7.3 mmol) in ethanol with stirring. The mixture was stirred at 160° C. for 3 hours. After cooling, a cold solution of 10% hydrochloric acid was added to the mixture. The resulting precipitate was recovered by filtration, dissolved in methanol and treated with active carbon. After evaporating in vacuo, the residue was recrystallized from ethyl acetate to give the title compound in a yield of 81%. 1H-NMR(DMSO-d6) δ 1.28 (6H, d, CH(CH3)2), 2.0 (3H, s, CH3), 3.07 (1H, septet, CH), 7.61 (5H, s, Ar—H), 7.6-7.7 (2H, m, H-7,8), 8.13 (1H, s, H-5), 12.67 (1H, s, NH)

[0060] Step 2. 1-ethyl-2-phenyl-3-methyl-6-isopropyl-1,4-dihydro-4-oxoquinoline

[0061] To a solution of 0.28 g(1 mmol) of 2-phenyl-3-methyl-6-isopropyl-1,4-dihydro-4-oxoquiline in DMF (10 mL) were added potassium carbonate(3 mmol) and ethyl iodide(5 mmol). The mixture was heated with stirring for 4.5 hours. After removing the solvent, the residue was dissolved in water and extracted with ethyl acetate twice. The combined organic layers were washed with water and then saturated sodium chloride solution followed by drying with sodium sulfate and evaporation in vacuo. The residue was purified by silica gel-column chromatography(hexane:ethyl acetate=2:1) to yield the title compound. 1H-NMR (CDCl3) δ 1.1-1.4 (3H, t, NCH2CH3), 1.3-1.5 (6H, d, CH(CH3)2), 1.8 (3H, s, CH3), 2.7-3.4 (1H, m, CH), 3.8-4.2 (2H, q, NCH2), 7.1-7.8 (7H, m, Ar—H), 8.3-8.6 (1H, s, H-5).

Example 2

1-Ethyl-2-(3-methyl-4-methoxyphenyl)-3,5-dimethyl-6-isobutoxy-1,4-dihydro-4-oxoquinoline (Compound A191)

[0062] Step 1. 3′-Methyl-4′-methoxyacetophenone

[0063] To an ice-cooled solution of 3′-methyl-4′-hydroxyacetophenone(15 g, 100 mmol) in 100 mL of DMF was added 60% sodium hydride (2.4 g, 101 mmol) under argon atmosphere with stirring. After 30 minutes, methyl iodide(7.5 mL, 120 mmol) was added to the solution and allowed to react overnight at room temperature with stirring. The reaction mixture was evaporated to remove the solvent. The residue was dissolved in water and extracted with diethyl ether thrice. The combined organic layers were sequentially washed with water and saturated sodium chloride solution, dried with sodium sulfate and distilled under reduced pressure (116° C./0.2 mmHg) to obain the title compound in a yield of 71%. 1H-NMR (CDCl3) δ 2.24 (3H, s, CH3), 2.54 (3H, s, COCH3), 3.90 (3H, s, OCH3), 6.84 (1H, d, H-5′), 7.77 (1H, dd, H-2′), 7.82 (1H, dd, H-6′)

[0064] Step 2. 3-Methyl-4-methoxybenzoic Acid

[0065] To a suspension of bleaching powder(72 g, 500 mmol) in 270 mL of water was added a solution of potassium hydroxide (14 g, 250 mmol) and potassium carbonate (50.5 g 365 mmol) in 150 mL of water. The suspension was stirred for 2 hours under sealing and the filtered to remove precipitated calcium salt. The precipitate was washed with a small amount of water and washing was combined with the above filtrate. To the filtrate was added 3′-methyl-4′-methoxyacetophenone (27.3 g, 166 mmol) while stirring vigorously. The mixture was stirred overnight at room temperature. After adding sodium bisulfate (17.8 g 171 mmol), the reaction mixture was washed twice with diethyl ether. The aqueous layer was acidified with hydrochloric acid. The resulting crystals were filtered off followed by drying under reduce pressure to yield the title compound.

[0066] 1 H-NMR (CDCl3) δ 2,18 (3H, s, CH3), 3.89 (3H, s, OCH3), 7.02 (1H, d, H-5), 7.74 (1H, dd, H-2), 7.81 (1H, dd, H-6)

[0067] Step 3. Ethyl 3-methyl-4-methoxybenzoate

[0068] A solution of 3-methyl-4-methoxybenzoic acid (20 g,120 mmol) and ethyl orthoformate (19.6 g 132 mmol) in 300 mL of ethanol was refluxed overnight with the addition of concentrated sulfuric acid (4 mL) followed by evaporation in vacuo to remove the solvent. The residue was dissolved in water. The solution was made alkaline with sodium carbonate and extracted thrice with chloroform. The combined organic layers were sequentially washed with saturated sodium carbonate solution, water and saturated sodium chloride solution, dried with sodium sulfate and distilled under reduced pressure (185-190° C./0.3 mmHg) to give the title compound. 1H-NMR (CDCl3) δ 1,38 (3H, t, CH2CH3), 2.23 (3H, s, 3-CH3), 3.87 (3H, s, OCH3), 4.34 (2H, dq, CH2CH3), 6.82 (1H, d, H-5), 7.83 (1H, dd, H-2), 7.89 (1H, dd, H-6)

[0069] Step 4. Ethyl 2-(3-methyl-4-methoxybenzoyl)propionate

[0070] To a mixture of ethyl 3-methyl-4-methoxybenzoate (24.8 g 128 mmol) and 60% sodium hydride (3.1 g, 128 mmol) under argon atmosphere was added dropwise a solution of ethyl propionate (6.5 g, 64 mmol) in 200 mL of n-butyl ether with stirring while keeping the inner temperature at 90-100° C. Stirring was continued for additional 3 hours at 130° C. After cooling to room temperature, excessive sodium hydride in the reaction mixture was decomposed with ethanol. After the addition of water, the reaction mixture was neutrallized with hydrochloric acid and extracted with diethyl ether thrice. The combined organic layers were sequentially washed with saturated sodium carbonate solution, water and saturated sodium chloride solution followed by drying with sodium sulfate. Distillation of the organic layers under reduced pressure (185-190° C./0.3 mmHg) gave the title compound. 1H-NMR (CDCl3) δ 1.19 (3H, t, CH2CH3), 1.47 (3H, d, CHCH3), 2,25 (3H, s, 3′-CH3), 3.90 (3H, s, OCH3), 4.15 (2H, dq, CH2CH3), 4.34 (1H, q, CH), 6.86 (1H, d, H-5′), 7.80 (1H, dd, H-2′), 7.86 (1H, dd, H-6′)

[0071] Step 5. 3-Methyl-4-isobutoxynitrobenzene

[0072] Isobutyl alcohol (1.5 g, 5 mmol) was dissolved in anhydrous DMF under argon atmosphere and cooled to −15° C. To this solution was added 60% sodium hydride (0.37 g, 15.5 mmol) with stirring followed by 2-nitro-5-fluorotoluene (2 g, 13 mmol) after 30 minutes. The mixture was stirred for additional 2 hours at the same temperature followed by distilling off DMF. The residue was diluted with water and extracted with chloroform thrice. The combined organic layers were was sequentially washed with water and saturated sodium chloride solution, dried with sodium sulfate and purified by silica gel-column chromatography (chloroform) to give the titel compound. 1H-NMR (CDCl3) δ 1.07 (6H, d, (CH3) 2), 2.16 (1H, septet, CH), 2.29 (3H, s, 3-CH3), 3.83 (2H, d, CH2), 6.82 (1H, d, H-5), 8.04 (1H, d, H-2), 8.08 (1H, dd, H-6)

[0073] Step 6. 3-methyl-4-isobutoxyaniline

[0074] To a solution of 3-methyl-4-isobutoxynitrobenzene (2.72 g, 13 mmol) in ethanol (25 mL) were added iron powder (13 g), water (1.5 mL) and concentrated hydrochloric acid (0.13 mL). The mixture was refluxed for 1 hour and then filtered while hot. The filtrate was concentrated in vacuo. The residue was dissolved in chloroform followed by drying with sodium sulfate. Removal of chloroform by evaporation gave the title compound. 1H-NMR (CDCl3) δ 1.01 (6H, d, CH(CH3)2), 2.06 (1H, septet, CH), 2.17 (3H, s, 3-CH3), 3.33 (2H,brs,NH2), 3.63 (2H, d, CH2), 6.53 (1H, d, H-2), 6.63 (1H, d, H-5), 6.67 (1H, dd, H-6)

[0075] Step 7. 2-(3-Methyl-4-methoxyphenyl)-3,5-dimethyl-6-isobutoxy-1,4-dihydro-4-oxoquinoline

[0076] To polyphosphoric acid (3 g) heated to 160° C. was added dropwise a solution of ethyl 2-(3-methyl-4-methoxybenzoyl) propionate (3,4 g,13.4 mmol) and 3-methyl-4-isobutoxyaniline (1.2 g, 6.7 mmol) in ethanol (2 mL) with stirring.

[0077] The mixture was stirred for additional 1 hour and allowed to cool to room temperature. An amount of crashed ice and 20% hydrochloric acid were added to the reaction mixture and extracted with chloroform. The organic layer was washed sequentially with saturated sodoium carbonate solution, water and saturated sodium chloride solution followed by drying with sodium sulfate. The residue resulting from evaporation of chloroform was roughly purified by silica gel-column chromatography(chloroform: acetone=20:1).

[0078] The title compound was obtained by crystallizing the crude product from diethyl ether. 1H-NMR (CDCl3) δ 1.08 (6H, d, CH(CH3)2), 1.87 (3H, s, 3-CH3), 2.07 (3H, s, 3′-CH3), 2,14 (1H, septet, CH), 2.91 (3H, s, 5-CH3), 3.75 (2H, d, CH2), 3.76 (3H, s, OCH3), 6.65 (1H, s, H-5′), 7.11 (1H, d, H-2′), 7.13 (1H, dd, H-6′), 7.21 (1H, d, H-8), 7.48 (1H, d, H-7), 9.78 (1H, s, NH)

[0079] Step 8. 1-Ethyl-2-(3-methyl-4-methoxyphenyl)-3,5-dimethyl-6-isobutoxy-1,4-dihydro-4-oxoquinoline

[0080] 2-(3-Methyl-4-methoxyphenyl)-3,5-dimethyl-6-isobutoxy-1,4-dihydro-4-oxoquinoline(0.18 g, 0.5 mmol) was dissolved in anhydrous DMF under argon atmosphere.

[0081] To the solution were added while ice cooling and stirring 60% sodium hydride (0.013 g, 0.54 mmol). After 30 minutes, ethyl iodide (0.12 g, 0.75 mmol) was added to the mixture followed by stirring overnight. After removing DMF by distillation, water was added to the reaction mixture followed by extraction with ethyl acetate thrice. The combined organic layers were washed sequentially with water and saturated sodium chloride solution, dried with sodium sulfate and then concentrated in vacuo. The residue was purified by silica gel-column chromatography (n-hexane:ethyl acetate=3:1) to give the title compound. 1H-NMR (CDCl3) δ 1.08 (6H, d, CH(CH3)2), 1.19 (3H, t, CH2CH3), 1.77 (3H, s, 3-CH3), 2.15 (1H, septet, CH), 2.28 (3H, s, 3′-CH3), 2.98 (3H, s, 5-CH3), 3.78 (2H, d, OCH2), 3.91 (3H, s, OCH3), 3.96 (3H, q, CH2CH3), 6.93 (1H, d, H-5′), 7.03 (1H, d, H-2′), 7.05 (1H, dd, H-6′), 7.25 (1H, d, H-8), 7.33 (1H, d, H-7)

Example 3

1-(4-chlorophenyl)-2-phenyl-3-methyl-6-isopropyl-1,4-dihydro-4-oxoquinoline(Compound A324)

[0082] Step 1. 4-Isopropylacetanilide

[0083] To a solution of 4-isopropylaniline (5.2 g, 38 mmol) in acetic acid was added while ice-cooling and stirring acetic anhydride (4 ml, 42 mmol). After stirring at room temperature overnight, the reaction mixture was poured into ice water. The resulting precipitate was filtered off, washed with water and then dried under reduced pressure to give the title compound. 1H-NMR (CDCl3) δ 1.22 (6H, d, CH(CH3)2), 2.15 (3H, s, NHCOCH3), 2.87 (1H, septet, CH), 7.28 (4H, d, Ar—H)

[0084] Step 2. 1-(4-Chlorophenyl)-4-isopropylacetanilide

[0085] Under argon atmosphere, a mixture of 4-isopropyl-acetanilide (2.5 g, 5 mmol), 4-chlorobromobenzene (2.97 g, 15.5 mmol), cupric iodide (2.95 g, 15.5 mmol) and potassium carbonate (1.5 g, 10.9 mmol) was heated at 160-180° C. for 30 hours followed by allowing to cool. The reaction mixture was diluted with water and diethyl ether and filtered to remove insolubles. The organic layer was separated, washed with water and saturated sodium chloride solution and dried with sodium sulfate. After removing the solvent, the residue was purified by silica gel-column chromatography (chloroform) to yield the title compound.

[0086] 1 H-NMR (CDCl3) δ 1.25 (6H, d, CH(CH3)2), 2.05 (3H, s, NCOCH3), 2.92 (4H, septet, CH), 7.15-7.28 (8H, m, Ar—H)

[0087] Step 3. 1-(4-Chlorophenyl)-4-isopropylaniline

[0088] A solution of 1-(4-chlorophenyl)-4-isopropylacetanilide (2.91 g, 10 mmol) in ethanol (35 mL) was mixed with 15 mL of concentrated hydrochloric acid. The mixture was refluxed overnight and evaporated to remove ethanol. The resulting residue was diluted with water and made alkaline with sodium hydroxide. This solution was extracted with diethyl ether twice. The combined organic layers were sequentially washed with water and saturated sodium chloride solution, dried with sodium sulfate and evaporated in vacuo to give the title compound. 1H-NMR (CDCl3) δ 1.24 (6H, d, CH(CH3)2), 2.87 (1H, septet, CH), 5,59 (1H, s, NH), 6.91-7.19 (8H, m, Ar—H)

[0089] Step 4. 1-(4-Chlorophenyl)-5-isopropylisatin

[0090] To a solution of 1-(4-chlorophenyl)-4-isopropylaniline (2.29 g, 9.3 mmol) in dry benzene under argon atmosphere was added oxalyl chloride (1.42 mL, 16.3 mmol) while ice cooling and stirring. The mixture was stirred at room temperature for additional 2 hours followed by evaporation under reduced pressure to remove excessive oxalyl chloride. The residue was dissolved in 1,2-dichloroethane. To this solution was added under argon atmosphere anhydrous aluminum chloride (1.28 g, 9.6 mmol) in portions. The mixture was stirred at room temperature overnight and then gradually poured into ice-water (40 mL) containing 10 mL of 2N hydrochloric acid solution. The organic phase was separated, sequentially washed with 2N sodium hydrogen carbonate solution, water and saturated sodium chloride solution, dried with sodium sulfate and evaporated under reduced pressure to remove 1,2-dichloroethane. The title compound was obtained by crystalizing the residue from diethyl ether, 1H-NMR (CDCl3) δ 1.24 (6H, d, CH(CH3)2, 2,92 (1H, septet, CH), 6.82 (1H, d, H-7), 7.36-7.55 (4H, m, Ar—H), 7.42 (1H, dd, H-6), 7.59 (1H, d, H-4)

[0091] Step 5. 1-(4-Chlorophenyl)-6-isopropylisatoic anhydride

[0092] A solution of 1-(4-chlorophenyl)-5-isopropylisatin (1.5 g, 5.0 mmol) in methylene chloride was added dropwise to a solution of m-chloroperbenzoic acid (907 mg, 5.3 mmol) in methylene chloride. The mixture was stirred at room temperature for 2 hours and then poured into ice-water containing 3 equivalents of sodium hydrogen sulfite followed by extraction with methylene chloride. The methylene chloride layer was sequentially washed with 1% sodium hydrogen carbonate solution, water and saturated sodium chloride solution, dried with sodium sulfate and then evaporated to remove methylene chloride. The title compound was obtained by crystallizing the residue from diethyl ether. 1H-NMR (CDCl3) δ 1.24 (6H, d, CH(CH3)2), 2.95 (1H, septet, CH), 6.49 (1H, d, H-8), 6.98 (1H, dd, H-7), 7.26-7.60 (4H, m, Ar—H), 8.03 (1H, d, H-5)

[0093] Step 6. 1-(4-Chlorphenyl)-2-phenyl-3-methyl-6-isopropyl-1,4-dihydro-4-oxoquinoline

[0094] Tetramethylethylenediamine (1.05 mL, 6.94 mmol) was gradially added with stirring into a solution of 1.55M hexane solution of n-butyl lithium (4.5 mL, 6.94 mmol) under argon atmosphere. Then a solution of propiophenone (936 mg, 6.94 mmol) in anhydrous THF was aded to the mixture while ice cooling and stirring. The reaction mixture was stirred for additional 3 hours at room temperatured and then ice-cooled.

[0095] To this was added dropwise a solution of 1-(4-chlorophenyl)-6-isopropylisatoic anhydride (1.10 g, 3.47 mmol) in anhydrous THF. The reaction mixture was stirred overnight at room temperature and diluted with saturated ammonium chloride. The organic layer was separated and concentrated in vacuo. The residue was dissolved in ethyl acetate. The resulting solution was washed with saturated sodium chloride solution, dried with sodium sulfate and evaporated to remove the solvent. The residue was purified by silica gel-column chromatography (chloroform:acetone=20: 1) followed by crystallization from diethyl ether to give the title compound. 1H-NMR (CDCl3) δ 1.31 (6H, d, CH(CH3)2), 1.91 (3H, s, CH3), 3.05 (1H, septet, CH), 6.67 (1H, d, H-8), 7.01-7.28 (9H, m, Ar—H), 7.33 (1H, dd, H-7), 8.39 (1H, d, H-5)

Example 4

1,2-Diphenyl-3-methyl-6-isopropyl-1,4-dihydro-4-oxoquinoline (Compound A320)

[0096] Step 1. 4-Isopropylisonitrosoacetanilide

[0097] A solution of chloral hydrate (9.0 g, 54 mmol) and anhydrous sodium sulfate (57 g) in 190 mL of water was heated to 60° C. . To this solution were added a warmed solution (70° C.) of 4-isopropylaniline (6.8 g, 50 mmol) and concentrated hydrochloric acid (4.3 mL, 52 mmol) in 150 mL of water followed by a warmed solution of hydroxylamine hydrochloride (11.0 g, 158 mmol) in 50 mL of water. The resulting solution was heated to boiling temperature over 40 minutes and then refluxed for 2 minutes. After cooling with tap water, the resulting precipitate was filtered off, washed with cold water and dried under reduced pressure to give the title compound. 1H-NMR (CDCl3) δ 1.21 (6H, d, CH3), 2.96 (1H, septet, CH), 6.72 (1H, brs, OH), 7.18 (2H, d, H-3.5), 7.47 (2H, d, H-2,6), 7.58 (1H, s, CH═N), 8.34 (1H, s, NH)

[0098] Step 2. 5-Isopropylisatin

[0099] 30 mL of concentrated sulfuric acid was heated to 50° C. To this was added 4-isopropylnitrosoacetanilide (8.4 g, 41 mmol) in portions while maintaing the inner temperature at 60-70° C. . The reaction mixture was heated at 80° C. for 10 minutes with stirring, allowed to cool to room temperature and poured into ice(about 300 g). The resulting precipitate was filtered off, washed with cold water and dried under reduced pressure to give the title compound. 1H-NMR (CDCl3) δ 1.21 (6H, d, CH2), 2.96 (1H, septet, CH), 7.10 (1H, d, H-8), 7.67 (1H, d, H-7), 7.74 (1H, d, H-5), 11.66 (1H,brs,NH)

[0100] Step 3. 1-Phenyl-5-isopropylisatin

[0101] A solution of 5-isopropylisatin (500 mg, 2.6 mmol), bromobenzene(10 mmol) and cupric iodide (420 mg, 5.3 mmol) in DMF was heated at 180° C. for 5.5 hours with stirring. The reaction mixture was filtered while hot and the filtrate was concentrated in vacuo. The residue was dissolved in chloroform followed by drying with sodium sulfate. The chloroform solution was evaporated to remove the solvent and the residue was purified by silica gel-chromatography (chloroform) to give the title compound. 1H-NMR (CDCl3) δ 1.25 (6H, d, CH(CH3)2, 2.92 (1H, septet, CH), 6.83 (1H, d, H-7), 7.38-7.57 (6H, m, Ar—H), 7.59 (1H, d, H-4)

[0102] Steps 4 and 5. 1,2-Diphenyl-3-methyl-6-isopropyl-1,4-dihydro-4-oxoquinoline

[0103] The title compound was prepared from 1-phenyl-5-isopropylisatin in a manner analogous to steps 5 and 6 of Example 3. 1H-NMR (CDCl3) δ 1.31 (6H, d, CH(CH3)2), 1.93 (3H, s, CH3), 3.05 (1H, septet, CH), 6.69 (1H, d, H-8), 7.04-7.33 (1H, m, Ar—H)

Example 5

1-Methyl-2-phenyl-3-ethoxycarbonyl-6-isopropyl-1,4-dihydro-4-oxoquinoline (Compound A50)

[0104] Step 1. 6-Isopropylisatoic Anhydride

[0105] To a solution of m-chloroperbenzoic acid (5 g, 28.5 mmol) in THF (20 mL) was added dropwise a solution of 5-isopropylisatin (2.7 g, 14.3 mmol) in THF (50 mL) under ice-cooling and stirring. After stirring for additional 3 hours under ice-cooling, the reaction mixture was treated with 10% sodium hydrogen sulfite solution (60 mL) to decompose excessive m-CPBA. The solution was poured into ice water (200 mL) and extracted with ethyl acetate several times. The combined organic layers were washed with water and saturated sodium chloride solution, dried with sodium sulfate and concentrated in vacuo. The resulting residue was crystallized from diethyl ether to give the title compound. 1H-NMR (CDCl3) δ 1.23 (6H, d, CH(CH3)2), 2.88 (1H, septet, CH), 6.95 (1H, d, H-7), 7.43 (1H, dd, H-6), 7.47 (1H, d, H-4)

[0106] Step 2. 1-Methyl-6-isopropylisatoic Anhydride

[0107] To a suspension of 60% sodium hydride (0.54 g, 13.4 mmol) in anhydrous DMF(30 mL), 6-isopropylisatoic anhydride (2.5 g, 12.2 mmol) was added at room temperature under argon atmosphere with stirring. After 30 minutes, methyl iodide (1.9 g, 13.4 mmol) was added to the reaction mixture followed by stirring at room temperature overnight. The reaction mixture was evaporated to remove DMF and extracted with chloroform. The extract was washed with water and saturates sodoium chloride solution, dried with sodium sulfate and evaporated in vacuo to dryness. The titled compound was obtained by crystalling the residue from diethyl ether. 1H-NMR (CDCl3) δ 1.28 (6H, d, CH(CH3)2), 2.99 (1H, septet, CH), 3.57 (3H, s, N—CH3), 7.12 (1H, d, H-8), 7.64 (1H, dd, H-7), 8.01 (1H, d, H-5)

[0108] Step 3. 1-Methyl-2-phenyl-3-ethoxycarbonyl-6-isopropyl-1,4-dihydro-4-oxoquinoline

[0109] To a suspension of 60% sodium hydride (0.06 g, 1.5 mmol) in anhydrous DMF (10 mL) was added ethyl benzoylacetate (0.29 g, 1,5 mmol) at room temperature under argon atmosphere with stirring. After 30 minutes, 1-metyl-6-isopropylisatoic anhydride (0.33 g, 1,5 mmol) was added to the mixture at 60° C. with stirring. The temperature was raised to 120° C. over 1 hour. The stirring was continued at the same temperature for additional 4 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel-chromatography (chloroform: acetone=9:1) followed by crystallization from diethyl ether to obtain the desired compound. 1H-NMR (CDCl3) δ 0.93 (3H, t, CH2CH3), 1.35 (6H, d, CH(CH3)2, 3.09 (1H, septet, CH), 3.98 (2H, q, OCH3), 7.39-7.41 (2H, m,H-2′,6′), 7.47-7.50 (4H, m, H-3′,4′,5′,8′), 7.61 (1H, dd, H-7), 8.40 (1H, d, H-5)

Example 6

1-Ethyl-2-(2-furyl)-6-isopropyl-1,4-dihydro-4-oxoquinoline (Compound A304)

[0110] Step 1. 1-Ethyl-6-isopropylisatoic Anhydride

[0111] 6-Propylisatoic anhydride was reacted with ethyl iodide in the presence of sodium hydride in a manner analogous to step 2 of Example 5 to prepare the title compound. 1H-NMR (CDCl3) δ 1.28 (6H, d, CH(CH3)2), 1.38 (3H, t, CH2CH3), 2.99 (1H, septet, CH), 4.13 (2H, q, NCH2), 7.14 (1H, d, H-8), 7.64 (1H, dd, H-7), 8.01 (1H, d, H-5)

[0112] Step 2. 1-Ethyl-2-(2-furyl)-6-isopropyl-1,4-dihydro-4-oxoquinoline

[0113] To a 1.6M solution of n-butyl lithium in hexane (1,38 mL, 2,2 mmol) was added tetramethylethylenediamine (0.3 mL, 2,2 mmol) under argon atmosphere at room temperature with stirring. Then 2-acetylfuran (242 mg, 2,2 mmol) in anhydrous THF was added dropwise to the mixture under ice cooling followed by stirring for 1 hour. To this mixture was added 1-ethyl-6-isopropylisatoic anhydride (250 mg, 1.1 mmol) in anhydrous THF. After stirring at room temperature overnight, the reaction mixture was diluted with saturated aqueous solution of ammonium chloride. The resulting organic layer was separated and concentrated under reduced pressure. The residue was dissolved in ethyl acetate and then washed with saturated sodium chloride solution followed by drying with sodium sulfate. After removing ethyl acetate by evaporation in vacuo, the residue was subjected to preparative TLC(n-hexane:ethyl acetate=2:1) to separate the title compound followed by crystallization from diethyl ether. 1H-NMR (CDCl3) δ 1.33 (6H, d, CH(CH3)2), 1.55 (3H, t, CH2CH3), 3.08 (1H,septet,CH), 4.17 (2H, q, NCH2), 6.48 (1H, s, H-3), 6.56-6.58 (1H, m, furan H-4′), 6.76 (1H, dd, furan H-5′), 7.54 (1H, d, H-8), 7.59 (1H, dd, H-7), 7.63 (1H, dd, furan H-3′), 8.34 (1H, d, H-5)

[0114] The following compounds have been produced in a manner analogous to that described in the preceding examples. 17

TABLE I
Com-
pound					m.p.
No.	R1	X	R3′	R4	(° C.)
A12	6-Br	H	H	CH3	166-168
A13	5-OH	H	CH3	CH3	282-283
A14	6-OH	H	CH3	CH3	>300
A15	7-OH	H	CH3	CH3	>300
A16	8-OH	H	CH3	CH3	240-242
A17	6-CH3	H	H	C2H5	169-170
A18	6-CH3	H	CH3	C2H5	167-170
A19	5-CH3O	H	CH3	CH3	141-142
A20	6-CH3O	H	CH3	CH3	154-156
A21	6-CH3O	3-CH3	H	C2H5	193-194
		4-CH3O
A22	6-CH3O	3-CH3	H	C2H5	140-142
		4-i-C3H7O
A23	6-CH3O	3-CH3	H	C2H5	144-145
		4-i-C4H9O
A24	7-CH3O	H	CH3	CH3	188-191
A25	8-CH3O	H	CH3	CH3	131-133
A26	6-C2H5	H	CH3	C2H5	151-154
A27	6-C2H5O	H	H	CH3	156-159
A28	6-C2H5O	H	CH3	C2H5	165-167
A29	6-C3H7	H	CH3	CH3	127
A30	6-C3H7	R	CH3	C2H5	133-134
A31	6-C3H7O	H	CH3	CH3	162-163
A32	6-C3H7O	H	CH3	C2H5	136-140
A33	5-i-C3H7	H	CH3	CH3	153-155
A34	5-i-C3H7	H	CH3	C2H5	144
A35	6-i-C3H7	H	H	CH3	140-141
A36	6-i-C3H7	H	CH3	CH3	197-199
A37	6-i-C3H7	H	CH3	C2H5	159-165
A38	6-i-C3H7	H	CH3	i-C3H7	184-186
A39	6-i-C3H7	H	CH3O	CH3	169-173
A40	6-i-C3H7	H	C2H5	CH3	172
A41	6-i-C3H7	H	C2H5	C2H5	129-130
A42	6-i-C3H7	H	C3H7	CH3	102-103
A43	6-i-C3H7	H	C3H7	C2H5	oil
A44	6-i-C3H7	H	i-C3H7	CH3	177-179
A45	6-i-C3H7	H	i-C3H7	C2H5	148
A46	6-i-C3H7	H	C4H9	CH3	136-137
A47	6-i-C3H7	H	C4H9	C2H5	oil
A48	6-i-C3H7	H	C6H13	CH3	84-86
A49	6-i-C3H7	H	C6H13	C2H5	oil
A50	6-i-C3H7	H	C2H5OCO	CH3	164-165
A51	6-i-C3H7	H	CH3SO2	CH3	245-247
A52	6-i-C3H7	H	CN	CH3	250-251
A53	6-i-C3H7	H	CH3CO	CH3	169-171
A54	6-i-C3H7	3-Cl	CH3	C2H5	159-160
A55	6-i-C3H7	4-Cl	H	CH3	149-152
A56	6-i-C3H7	4-Cl	H	C2H5	172-173
A57	6-i-C3H7	4-Cl	CH3	CH3	231-232
A58	6-i-C3H7	4-Cl	CH3	C2H5	204-205
A59	6-i-C3H7	3-F	CH3	CH3	263
A60	6-i-C3H7	3-F	CH3	C2H5	174-175
A61	6-i-C3H7	3,4-diCl	H	CH3	207-210
A62	6-i-C3H7	3,4-diCl	CH3	CH3	268-270
A63	6-i-C3H7	3,4-diCl	H	C2H5	160-162
A64	6-i-C3H7	3,4-diCl	CH3	C2H5	197-198
A65	6-i-C3H7	3,4-diF	CH3	CH3	278-279
A66	6-i-C3H7	3,4-diF	CH3	C2H5	194-196
A67	6-i-C3H7	3-CF3	CH3	CH3	200-201
A68	6-i-C3H7	3-CF3	CH3	C2H5	179
A69	6-i-C3H7	4-CF3	CH3	CH3	>300
A70	6-i-C3H7	4-CF3	CH3	C2H5	218-219
A71	6-i-C3H7	2-OH	H	CH3	>300
A72	6-i-C3H7	3-OH	H	CH3	248-249
A73	6-i-C3H7	4-OH	H	CH3	>300
A74	6-i-C3H7	4-OH	CH3	CH3	>300
A75	6-i-C3H7	2-CH3	CH3	C2H5	157-159
A76	6-i-C3H7	3-CH3	CH3	CH3	181-183
A77	6-i-C3H7	3-CH3	CH3	C2H5	140-144
A78	6-i-C3H7	3-CH3O	CH3	C2H5	130-132
A79	6-i-C3H7	4-CH3	CH3	CH3	180-181
A80	6-i-C3H7	4-CH3	CH3	C2H5	171-172
A81	6-i-C3H7	4-CH3O	CH3	CH3	177-178
A82	6-i-C3H7	4-CH3O	CH3	C2H5	193-196
A83	6-i-C3H7	4-CH3O	CH3	C3H7	199-202
A84	6-i-C3H7	4-C2H5	CH3	CH3	193-194
A85	6-i-C3H7	4-C2H5	CH3	C2H5	148-150
A86	6-i-C3H7	4-C2H5O	CH3	CH3	169-170
A87	6-i-C3H7	4-C2H5O	CH3	C2H5	173-175
A88	6-i-C3H7	4-C3H7	CH3	CH3	181-183
A89	6-i-C3H7	4-C3H7	CH3	C2H5	88-91
A90	6-i-C3H7	4-C3H7O	CH3	CH3	164-166
A91	6-i-C3H7	4-C3H7O	CH3	C2H5	125-127
A92	6-i-C3H7	4-C3H11	CH3	CH3	159-160
A93	6-i-C3H7	4-C5H11	CH3	C2H5	110-113
A94	6-i-C3H7	4-C5H11O	CH3	CH3	137-138
A95	6-i-C3H7	4-C5H11O	CH3	C2H5	255-257
A96	6-i-C3H7	3-CH3	H	CH3	248-250
		4-OH
A97	6-i-C3H7	3-CH3	H	CH3	209-210
		4-CH3O
A98	6-i-C3H7	3-CH3	H	C2H5	128-129
		4-CH3O
A99	6-i-C3H7	3-CH3	H	CH3	134-135
		4-C2H5O
A100	6-i-C3H7	3-CH3	H	CH3	130-131
		4-i-C3H7O
A101	6-i-C3H7	3-CH3O	H	CH3	293-295
		4-OH
A102	6-i-C3H7	3-C2H5	H	CH3	155-157
		4-CH3O
A103	6-i-C3H7	3-C2H5	H	CH3	147-150
		4-i-C3H7O
A104	6-i-C3H7	3-C2H5	H	CH3	149-153
		4-
		CH3COO
A105	6-i-C3H7	3-i-C3H7	H	CH3	180-182
		4-CH3O
A106	6-i-C3H7	2,3-diCH3	CH3	CH3	185-187
A107	6-i-C3H7	2,4-diCH3	CH3	CH3	151-152
A108	6-i-C3H7	2,4-diCH3	CH3	C2H5	121
A109	6-i-C3H7	2,5-diCH3	CH3	CH3	143-145
A110	6-i-C3H7	3,4-diCH3	CH3	CH3	154-156
A111	6-i-C3H7	3,4-diCH3	CH3	C2H5	119-121
A112	6-i-C3H7	3,5-diCH3	CH3	C2H5	151-155
A113	6-i-C3H7	3-OH	CH3	CH3	295
		4-CH3
A114	6-i-C3H7	3-OH	CH3	CH3	227-228
		4-CH3O
A115	6-i-C3H7	3-CH3	CH3	C2H5	158-160
		4-CH3O
A116	6-i-C3H7	3-CH3	C2H5OCO	C2H5	179-180
		4-CH3O
A117	6-i-C3H7	3-CH3O	CH3	CH3	166
		4-CH3
A118	6-i-C3H7	3-CH3O	CH3	C2H5	164-166
		4-CH3
A119	6-i-C3H7O	3-CH3	H	C2H5	177-178
		4-CH3O
A120	6-i-C3H7O	3-CH3	H	C2H5	123-124
		4-i-C3H7O
A121	7-i-C3H7	H	CH3	CH3	156-157
A122	7-i-C3H7	H	CH3	C2H5	142-144
A123	7-i-C4H9O	H	CH3	CH3	179-182
A124	6-C4H9	H	CH3	CH3	140
A125	6-C4H9	H	CH3	C2H5	85-86
A126	6-C4H9O	H	CH3	CH3	126-128
A127	6-C4H9O	H	CH3	C2H5	136-138
A128	6-i-C4H9	H	CH3	C2H5	121-125
A129	6-i-C4H9O	H	CH3	CH3	oil
A130	6-i-C4H9O	H	CH3	C2H5	106-107
A131	6-i-C4H9O	H	CH3	2-	97-101
				butenyl
A132	6-i-C4H9O	H	CH3	benzyl	178-181
A133	6-i-C4H9O	3-CH3	H	CH3	167-168
		4-CH3O
A134	6-i-C4H9O	3-CH3	H	C2H5	169-170
		4-CH3O
A135	6-i-C4H9O	3-CH3	CH3	C2H5	180-182
		4-CH3O
A136	6-i-C4H9O	3-CH3	H	C2H5	116-118
		4-C4H9O
A137	6-C5H11	H	CH3	CH3	138-140
A138	6-C5H11	H	CH3	C2H5	94-96
A139	6-C5H11O	H	CH3	CH3	115-117
A140	6-i-C5H11	H	CH3	CH3	138-139
A141	6-i-C5H11	H	CH3	C2H5	101-103
A142	6-i-C5H11O	H	CH3	CH3	112-113
A143	6-i-C5H11O	H	CH3	C2H5	128-130
A144	6-C5H13	H	OH3	CH3	123-125
A145	6-C5H13	H	CH3	C2H5	oil
A146	6-C5H13O	H	CH3	CH3	100-102
A147	6-C5H13O	H	CH3	C2H5	96-98
A148	6-i-C5H13O	H	CH3	CH3	106-109
A149	6-C8H17	H	CH3	CH3	105-107
A150	6-C8H17	H	CH3	C2H5	oil
A151	6-cyclohexyl	H	CH3	CH3	221-222
A152	6-cyclohexyl	H	CH3	C2H5	154-156
A153	6-NO2	H	CH3	CH3	279
					(dec)
A154	6-NH2	H	CH3	CH3	227
A155	6-(CH3)2N	H	CH3	CH3	179-183
A156	6-N-(2-dimethyl	H	CH3	CH3	methyl-
	aminoethylamino				iodide
					285
					(dec)
A157	6-i-C4H9NH	H	CH3	CH3	183-186
A158	Compound No. 157 2HCl.½H2O	194
		(dec)
A159	6-i-C4H9NH	H	CH3	C2H5	H2O
					162
A160	6-i-C4H9NH	H	CH3	C2H5	HCl
					183
A161	6-pyrrolidino	H	CH3	CH3	157-167
A162	6-pyrrolidino	H	CH3	C2H5	122-130
A163	6-piperazino	H	CH3	CH3	186-196
A164	6-piperazino	H	CH3	C2H5	186-189
A165	6-(4-methyl	H	CH3	C2H5	111-113
	piperazino)
A166	6-(4-acetyl	H	CH3	CH3	220-225
	piperazino)
A167	6-(4-acetyl	H	CH3	C2H5	200-204
	piperazino)
A168	6-morpholino	H	CH3	CH3	241-243
A169	6-morpholino	H	CH3	C2H5	195-196
A170	6-C6H5	H	CH3	CH3	164-169
A171	6-C6H5	H	CH3	C2H5	192-194
A172	6-(3-pyridyl)	H	H	CH3	oil
A173	6-Cl	H	CH3	CH3	187-189
A174	6-Cl	H	CH3	C2H5	160-161
A175	6-F	H	CH3	CH3	192-193
A176	6-F	H	CH3	C2H5	193-196
A177	7-F	H	CH3	CH3	219-221
A178	5-Cl	H	CH3	CH3	207-208
	6-i-C4H9O
A179	5-Cl	H	CH3	C2H5	174-176
	6-i-C4H9O
A180	5-Cl	3-CH3	CH3	CH3	179-180
	6-i-C4H9O
A181	5-Cl	3-CH3	CH3	C2H5	167-167
	6-i-C4H9O
A182	5-F	H	CH3	CH3	172-173
	6-i-C4H9O
A183	5-F	4-O2H5	CH3	CH3	205-207
	6-i-C4H9O
A184	5-CH3	3-CH3	CH3	C2H5	165-167
	6-CH3O	4-CH3
A185	5-CH3	3-CH3	CH3	C2H5	175-176
	6-i-C3H7O	4-i-C3H7O
A186	5-CH3	H	H	CH3	127
	6-i-C4H9O
A187	5-CH3	H	H	C2H5	182-184
	6-i-C4H9O
A188	5-CH3	H	CH3	C2H5	154-156
	6-i-C4H9O
A189	5-CH3	3-CH3	H	C2H5	185-186
	6-i-C4H9O	4-CH3O
A190	5-CH3	3-CH3	CH3	CH3	150-151
	6-i-C4H9O	4-CH3O
A191	5-CH3	3-CH3	CH3	C2H5	149
	6-i-C4H9O	4-CH3O
A192	5-CH3	3-CH3	CH3	C2H5	169-171
	6-i-C4H9O	4-i-C3H7O
A193	5-CH3	3-CH3	H	C2H5	114-115
	6-i-C4H9O	4-i-C3H7O
A194	5-NH2	H	CH3	CH3	HCl
	6-i-C4H9O				130-131
A195	5-i-C3H7	H	CH3	CH3	153-155
	6-CH3O
A196	5-CH3O	H	CH3	CH3	130-131
	6-i-C4H9O
A197	5-i-C4H9O	H	CH3	CH3	oil
	6-F
A198	5-(N-methyl-N-	H	CH3	CH3	120-122
	(2-dimethyl-
	amino-
	ethyl)amino)
	6-F
A199	5,7-diF	H	CH3	CH3	218-220
A200	5,7-diCH3O	H	CH3	CH3	220
A201	5-i-C4H9O	H	CH3	CH3	120
	7-F
A202	6,7-diF	H	CH3	CH3	194-197
A203	6-F	H	CH3	CH3	216-219
	7-i-C4H9O
A204	6-F	H	CH3	CH3	189-194
	7-piperidino
A205	6-F,7-(4-hydro-	H	CH3	CH3	>300
	xypiperidino)
A206	6-F	H	CH3	CH3	221-225
	7-pyrrolidino
A207	6-F	H	CH3	CH3	251-252
	7-morpholino
A208	6-F	H	CH3	CH3	223-226
	7-piperazino
A209	6-F	H	CH3	CH3	202-205
	7-(4-methyl-
	piperazino)
A210	6-F	H	CH3	CH3	215-218
	7-(4-acetyl-
	piperadino)
A211	6-F,7-[N-methyl-	H	CH3	CH3	189-190
	N-(2-hydroxy-
	ethyl)amino
A212	6-OH	H	CH3	CH3	>300
	7-F
A213	6-OH	H	CH3	CH3	>300
	7-i-O3H7
A214	6-CH3O	H	CH3	CH3	210-213
	7-F
A215	6-C2H5O	H	CH3	CH3	266-267
	7-F
A216	6-C3H7O	H	CH3	CH3	198-200
	7-F
A217	6-C4H9O	H	CH3	CH3	146-148
	7-F
A218	6,7-OCH2O—	H	CH3	CH3	185-189
A219	6,7-	H	CH3	CH3	273-274
	OC2H4N(CH3)—
A220	6,7-diCH3O	H	CH3	CH3	282-283
A221	6,7-diC2H5O	H	CH3	CH3	219-221
A222	6,7-diC3H7O	H	CH3	CH3	187-189
A223	6,7-di-i-C4H9O	H	CH3	CH3	218-220
A224	6-CH3O	H	CH3	CH3	202-206
	7-C3H5
A225	6-CH3O	H	CH3	CH3	175-177
	7-C3H7
A226	6-CH3O	H	CH3	CH3	174-177
	7-i-C3H7
A227	6-CH3O	H	CH3	C2H5	133-134
	7-i-C3H7
A228	6-CH3O	4-C2H5	CH3	CH3	172-175
	7-i-C3H7
A229	6-CH3O	4-i-C3H7	CH3	CH3	182-183
	7-i-C3H7
A230	6-CH3O	3-CH3	H	CH3	197-199
	7-i-C3H7	4-CH3O
A231	6-CH3O	3-CH3	CH3	CH3	200
	7-i-C3H7	4-CH3O
A232	6-CH3O	3-CH3	CH3	C2H5	170-171
	7-i-C3H7	4-CH3O
A233	6-i-C4H9O	H	H	CH3	156-157
	7-CH3
A234	6-i-C4H9O	H	CH3	CH3	202-204
	7-CH3
A235	6-i-C4H9O	H	CH3	C2H5	142-144
	7-CH3
A236	6-i-C4H9O	3-CH3	H	CH3	219-220
	7-CH3	4-CH3O
A237	6-i-C4H9O	3-CH3	CH3	CH3	178-179
	7-CH3	4-CH3O
A238	6-i-C4H9O	3-CH3	CH3	C2H5	196
	7-CH3	4-CH3O
A239	6-CH3O	H	CH3	CH3	239-242
	7-CH3H5O
A240	6-CH3O	H	CH3	CH3	215-222
	7-C3H7O
A241	6-CH3O	H	CH3	CH3	213-216
	7-i-C4H9O
A242	6-CH3O	H	CH3	CH3	210-213
	7-CF3
A243	6-CH3O	H	CH3	CH3	229-231
	7-cyclohexyloxy
A244	6-CH3O	H	CH3	CH3	216-218
	7-C6H5O
A245	6-CH3O	H	CH3	CH3	>300
	7-(4-pyridyl)oxy
A246	6-CH3O	H	CH3	CH3	215-217
	7-pyrrolidino
A247	6-CH3O	H	CH3	CH3	230-237
	7-piperidino
A248	6-CH3O	H	CH3	CH3	246-248
	7-morpholino
A249	6-CH3O	H	CH3	CH3	234-236
	7-thiomorpholino
A250	6-CH3O	H	CH3	CH3	217-220
	7-piperazino
A251	6-CH3O	H	CH3	CH3	231-233
	7-(4-methyl-
	piperazino)
A252	6-CH3O	H	CH3	CH3	247-249
	7-(4-acetyl-
	piperazino)
A253	6-CH3O	H	CH3	CH3	252-254
	7-pyrrolyl
A254	6-CH3O	H	CH3	CH3	180-182
	7-(1-pyrazolyl)
A255	6-CH3O	H	CH3	CH3	254-257
	7-(1-imidazolyl)
A256	6-CH3O	H	CH3	CH3	241-245
	7-(1-triazolyl)
A257	6-C2H5O	H	CH3	CH3	128-130
	7-i-C3H7
A258	6-i-C3H7O	H	CH3	CH3	126-128
	7-i-C3H7
A259	6-i-C3H7O	H	CH3	CH3	126-128
	7-i-C3H7
A260	6-i-C4H9O	H	CH3	CH3	241-242
	7-CH3O
A261	6-i-C4H9O	H	CH3	CH3	134-137
	7-i-C3H7
A262	6-i-C4H9O	H	CH3	CH3	176-177
	7-CF3
A263	6-i-C4H9O	H	CH3	CH3	198-203
	7-pyrrolidino
A264	6-i-C4H9O	H	CH3	CH3	224-225
	7-piperidino
A265	6-i-C4H9O	H	CH3	CH3	216-219
	7-morpholino
A266	6-acetoxy	H	CH3	CH3	139
	7-CH3
A267	6-hydroxy-	H	CH3	CH3	>300
	carbonyloxy
	7-CH3
A268	6-ethoxy-	H	CH3	CH3	169-170
	carbonyloxy
	7-CH3
A269	6-hydroxy-	H	CH3	CH3	>300
	carbonylmethoxy
	7-CH3
A270	6-i-C3H7	H	CH3	C2H5	232
	7-CH3O
A271	6-ethoxy-	H	CH3	CH3	183-184
	carbonyloxy
	7-i-C3H7
A272	7,8-diF	H	CH3	CH3	226-228
A273	7-i-C3H7	H	CH3	CH3	144-145
	8-CH3O
A274	7-i-C3H7	4-C2H5	CH3	CH3	152-155
	8-CH3O
A275	7-i-C4H9	H	CH3	CH3	oil
	8-F
A276	5,7-diCl	H	CH3	CH3	223-226
	8-CH3O
A277	5,7-diCl	H	CH3	C2H5	180-182
	6-CH3O
A278	5,7-diCl	H	CH3	CH3	196-199
	6-i-C4H9O
A279	5,7-diCl	H	CH3	C2H5	193-194
	6-i-C4H9O
A280	5-Cl	H	CH3	CH3	184-186
	6-CH3O
	7-i-C3H7
A281	5-Cl	H	CH3	C2H5	154-155
	6-CH3O
	7-i-C3H7
A282	5-Cl	H	CH3	CH3	188-189
	6- i-C4H9O
	7-CH3
A283	5-Cl	H	CH3	C2H5	205-207
	6-i-C4H9O
	7-CH3
A284	5-Cl	H	CH3	C2H5	183-186
	6-i-C4H9O
	7-Cl
A285	5,7-diCH3	H	H	CH3	170-172
	6-i-C4H9O	H
A286	5,7-diCH3	H	CH3	CH3	158-160
	6-i-C4H9O
A287	5,7-diCH3	H	CH3	C2H5	175-178
	6-i-C4H9O
A288	5,7-diCH3	3-CH3	CH3	CH3	155-157
	6-i-C4H9O	4-CH3O
A289	5,7-diCH3	3-CH3	CH3	C2H5	154-157
	6-i-C4H9O	4-CH3O

[0115] 18

TABLE II
Com-
pound					m.p.
No.	R1	R2′	R3′	R4	(° C.)
A290	6-C3H7	CH3	C6H5	CH3	241-245
A291	6-i-C3H7	CH3	CH3	CH3	188-189
A292	6-i-C3H7	CH3	C4H9	CH3	106-107
A293	6-i-C3H7	CH3	C4H9	C2H5	oil
A294	6-i-C3H7	C3H7	H	CH3	132-134
A295	6-i-C3H7	2-pyridyl	H	CH3	124-126
A296	6-i-C3H7	2-pyridyl	H	C2H5	144-146
A297	6-i-C3H7	3-pyridyl	H	CH3	164-166
A298	6-i-C3H7	3-pyridyl	H	C2H5	148-149
A299	6-i-C3H7	3-pyridyl	CH3	CH3	242-243
A300	6-i-C3H7	4-pyridyl	H	CH3	192-193
A301	6-i-C3H7	4-pyridyl	H	C2H5	229-230
A302	6-i-C3H7	2-pyradinyl	H	C2H5	94-96
A303	6-i-C3H7	2-furyl	H	CH3	86-88
A304	6-i-C3H7	2-furyl	H	C2H5	70-73
A305	6-i-C3H7	N—CH3-	H	C2H5	101-104
		2-pyrrolyl
A306	6-i-C3H7	N—CH3-	H	CH3	173-176
		3-pyrrolyl
A307	6-i-C3H7	N—CH3-	H	C2H5	132-134
		3-pyrrolyl
A308	6-i-C3H7	2-thienyl	H	CH3	111-113
A309	6-i-C3H7	2-thienyl	H	C2H5	95-96
A310	6-i-C3H7	2-thienyl	CH3	CH3	136-137
A311	6-i-C3H7	2-thienyl	CH3	C2H5	169-173
A312	6-i-C3H7	3-thienyl	H	CH3	164-166
A313	6-i-C3H7	3-thienyl	H	C2H5	118-120
A314	6-i-C3H7	5-CH3-	H	CH3	132
		2-thienyl
A315	6-i-C3H7	5-CH3-	H	C2H5	121-122
		2-thienyl
A316	6-i-C3H7	5-Br-2-thienyl	H	CH3	183-185
A317	6-i-C3H7	5-Br-2-thienyl	H	C2H5	oil
A318	5-CH3	2-thiernyl	CH3	CH3	111-112
	6-i-C4H9O
A319	6-i-C3H7	2-thiazolyl	H	C2H5	91-93
A320	6-i-C3H7	C6H5	CH3	C6H5	225
A321	6-i-C3H7	C6H5	CH3	2-F—C6H4	205-207
A322	6-i-C3H7	C6H5	CH3	3-F—C6H4	248-251
A323	6-i-C3H7	C6H5	CH3	4-F—C6H4	224-229
A324	6-i-C3H7	C6H5	CH3	4-Cl—C6H4	233-235
A325	6-i-C3H7	C6H5	CH3	4-CH3—C6H4	203-205
A326	6-i-C3H7	C6H5	CH3	4-CH3O—	204-208
				C6H4

[0116] Part B. 19

Example 7

5-Ethyl-8-isopropyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one(Compound B2)

[0117] To a 1.6M solution of n-butyl lithium in hexane (6.6 mL, 10.5 mmol) was added tetramethylethylenediamine (1.58 mL, 10.5 mmol) under argon atomosphere at room temperature with stirring. To this was added with ice cooling a solution of 1-indanone (1.38 g, 10.5 mmol) in anhydrous THF followed by stirring at room temperature for 1 hour. After ice cooling the mixture, a solution of 1-ethyl-6-isopropylisatoic anhydride prepared in step 1 of Example 6 (1.22 g, 5.2 mmol) in anhydrous THF was added dropwise thereto. The mixture was stirred at room temperature overnight and then duluted with saturated aqueous solution of ammonium chloride. The organic layer was separated and concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with saturated sodium chloride solution and dried with sodium sulfate followed by evaporating to remove the solvent. The residue was purified by silica gel-chromatography (chloroform) and crystallization from diethyl ether to obtain the desired compound. 1H-NMR (CDCl3) δ 1.32 (6H, d, CH(CH3)2), 1.70 (3H, t, CH2CH3), 3.09 (1H, septet, CH), 3.91 (2H, s, H-11), 4.71 (2H, q, NCH2), 7.47-7.94 (6H, m, Ar—H), 8.44 (1H, s, H-9)

Example 8

2.5-Diethyl-8-isopropyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one (Compound B9)

[0118] Step 1. 3-Chloro-1-(4-ethylphenyl)-1-propanone

[0119] To a solution of anhydrous aluminum chloride (20 g, 0.15 mmol) in nitrobenzene(50 mL) was added dropwise a solution (30 mL) of ethylbenzene(13.5 mL, 0.11 mmol) and 3-chloropropionyl chloride (25 g, 0.20 mmol) in nitrobenzene. The mixture was stirred at room temperature for 3 hours and then poured into ice-water (600 mL) containing 100 mL of concentrated hydrochloric acid followed by extraction with diethyl ether. The combined organic layers were washed with water and saturated sodium chloride solution, dried with sodium sulfate and evoparated to remove diethyl ether and nitrobenzene under reduced pressure. The residue was crystallized from n-hexane to give the title compound (9.1 g, 42.1%). 1H-NMR (CDCl3) δ 1.26 (3H, t, CH2CH3), 2.72 (2H, q, CH2CH3), 3.44 (2H,t,COCH2), 3.93 (2H, t, CH2Cl), 7.31 (2H, d, Ar—H), 7.89 (2H, d, Ar—H)

[0120] Step 2. 5-Ethyl-1-indanone

[0121] 3-Chloro-1-(4-ethylphenyl)-1-propanone (9.1 g, 46.3 mmol) was dissolved in 50 mL of conc. H2SO4 and heated at 100° C. for 30 minutes with stirring. The reaction mixture was poured onto crashed ice (500 g). The resulting precipitate was filtered off, washed with water and then dissolved in diethyl ether. The solution was washed with water and saturated sodium chloride solution, dried with sodium sulfate and evaporated to dryness. The title compound was obtained by crystallizing the residue from n-hexane. 1H-NMR (CDCl3) δ 1.28 (3H, t, CH2CH3), 2.67-2.70 (2H, m,H-3), 2.74 (2H, q, CH2CH3), 3.11 (2H, dd, H-2), 7.21 (1H, d, Ar—H), 7.30 (1H, s, H-4), 7.68 (1H, d, Ar—H)

[0122] Step 3. 2,5-Diethyl-8-isopropyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one

[0123] To a 1.53M solution of n-butyl lithium in hexane (13.2 mL, 20.2 mmol) was added TMEDA (3.1 mL, 20.2 mmol) under argon atmosphere at room temperature with stirring. To this was added with ice cooling a solution of 5-ethyl-1-indanone(3.24 g,20.2 mmol) in anhydrous THF followed by stirring at room temperature for 1 hour. After ice cooling the mixture, a solution of 1-ethyl-6-isopropylisatoic anhydride (Example 6, step 1) (2.35 g, 10.1 mmol) in anhydrous THF was added dropwise thereto. The mixture was stirred at room temperature overnight and diluted with saturated aqueous solution of ammonium chloride. The orgaic layer was separated and concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with saturated sodium chloride solution and dried with sodium sulfate. After removing the solvent, the residue was purified by silica gel-chromatography (chloroform:acetone=20:1) and crystallization from diethyl ether to give the desired compound. 1H-NMR (CDCl3) δ 1.32 (3H, t, CH2CH3), 1.34 (6H, d, CH(CH3)2), 1.70 (3H, t, NCH2CH3), 2.78 (2H, q, CH2CH3), 3.10 (1H, septet, CH), 3.91 (2H, s, H-11), 4.72 (2H, q, NCH2), 7.30-7.85 (5H, m, Ar—H), 8.45 (1H, s, H-9)

Example 9

2-Ethyl-9-isopropyl-6,12-dihydrobenzo[c]acridin-7 (5H)-one (Compund B25)

[0124] To a 1.6M solution of n-butyl lithium in hexane (1.6 mL, 2.6 mmol) was added TMEDA (0.4 mL, 2.6 mmol) under argon atmosphere at room temperature with stirring. To this was added with ice cooling a solution of 1-tetralone (0.38 g, 2.6 mmol) in anhydrous THF followed by stirring for 1 hour under ice cooling. Thereafter, a solution of 1-ethyl-6-i-propylisatoic anhydride (0.3 g, 1.3 mmol) in anhydrous THF was added dropwise followed by stirring at room temperature for 1.5 hours. The reaction mixture was diluted with saturated aqueous solution of ammonium chloride. The organic layer was separated and concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with saturated sodium chloride solution and dried with sodium sulfate. After removing the solvent, the residue was purified by silica gel-chromatography (chloroform) followed by crystallization from petroleum ether to give the desired compound. 1H-NMR (CDCl3) δ 1.15 (3H, t, NCH2CH3), 1.33 (6H, d, CH(CH3)2), 2.79-2.86 (4H, m, CH2CH2), 3.07 (1H, septet, CH), 4.62 (2H, q, NCH2), 7.32-7.60 (6H, m, Ar—H), 8.33 (1H, d, H-8)

[0125] The following compounds have been synthesized in a manner analogous to Examples 7-9. 20

[0126] The numbering of various substituents are those of respective fused ring systems, namely indeno[1,2-b]quinoline(x=1),benzo[c]acridine(x=2) and benzo[6,7]cyclohepta[1,2-b]quinoline, respectively.

TABLE III
Com-
pound
No.	x	R4	R5	R1
B1	1	CH3	H	8-i-C3H7	249
					(dec)
B2	1	C2H5	H	8-i-C3H7	152-155
B3	1	Compound			175-177
		B2,
		HCl salt
B4	1	C2H5	H	8-CH3O	205-207
B5	1	C2H5	H	6-F	241-243
B6	1	CH3	H	8-CH3O	297
				9-i-C3H7	(dec)
B7	1	C2H5	H	8-CH3O	217-218
				9-i-C3H7
B8	1	CH3	2-C2H5	8-i-C3H7	220
					(dec)
B9	1	C2H5	2-C2H5	8-i-C3H7	205
B10	1	C2H5	2-CH3O	8-i-C3H7	202-204
B11	1	CH3	2-CH3O	8-i-C4H9	218
B12	1	C2H5	2-CH3O	8-i-C4H9	216-217
B13	1	CH3	2-CH3O	8-i-C3H7	215-222
B15	1	C2H5	2-CH3O	8-i-C4H9	189-190
B16	1	CH3	2-Cl	8-i-C3H7	265
					(dec)
B17	1	C2H5	2-Cl	8-i-C3H7	186
					(dec)
B18	1	CH3	2-Br	8-i-C3H7	280
					(dec)
B19	1	C2H5	2-Br	8-i-C3H7	225
					(dec)
B20	1	C2H5	2-OCH3	8-i-C3H7	217
			3-CH3		(dec)
B21	1	CH3	2,3-diCH3O	8-i-C3H7	253-254
B22	1	C2H5	2,3-diCH3O	8-i-C3H7	208
B23	1	C2H5	1,2-diCl	8-i-C3H7	235
					(dec)
B24	2	CH3	H	9-i-C3H7	199-203
B25	2	C2H5	H	9-i-C3H7	oil
B26	2	CH3	H	9-i-C4H9O	160
B27	2	C2H5	H	9-i-C4H9O	61
B28	3	CH3	H	10-i-C3H7	167
B29	1	4-FC6H4	2-CH3O	8-i-C3H7	285
					(dec)
B30	1	4-FC6H4	2-C2H5	8-i-C3H7	270
					(dec)
B31	1	C6H4	2-CH3O	8-i-C3H7	208-210
B32	1	C2H5	2-CH3O	7-i-C3H7	224-225
				8-CH3O
B33	1	C2H5	2-C2H5	7-i-C3H7	210-212
				8-CH3O
B34	1	C2H5	H	7,9-diCH3	184
				8-i-C4H9
B35	1	C2H5	2-CH3O	7,9-diCH3	203-204
				8-i-C4H9
B36	1	C2H5	2-C2H5	7,9-diCH3	140
				8-i-C4H9
B37	1	C2H5	1,3-diCH3	8-i-C3H7	201
			2-CH3O
B38	1	4-FC6H4	2-C2H5	7-i-C3H7	281
				8-CH3O	(dec)
B39	1	C2H5	H	8-i-C4H9O	239-240
				9-CH3

[0127] Part C. 21

Example 10

5-Ethyl-8-isopropyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10,11-dione (Compound C47)

[0128] Under argon atmosphere, 60% sodium hydride (82 mg, 2.0 mmol) was added to a solution of 1,3-indandione (300 mg,2.0 mmol) in anhydrous DMF with ice cooling and stirring followed by stirring for additional 1 hour. To the mixture was added dropwise a solution of 1-ethyl-6-isopropylisatoic anhydride (238 mg,1.0 mmol) in anhydrous DMF followed by stirring at 60° C. for 3 hours. The reaction mixture was poured into ice-water. The resulting precipitate was filtered off, washed with water and dissolved in chloroform. The chloroform solution was washed with saturated sodium chloride solution and dried with sodium sulfate followed by evaporation to remove chloroform. The title compound was obtained by crystallizing from diethyl ether. 1H-NMR (CDCl3) δ 1.30 (6H, d, CH(CH3)2, 1.73 (3H, t, NCH2CH3), 3.03 (1H, septet, CH), 4.69 (2H, q, NCH2), 7.46-7.71 (6H, m, Ar—H), 8.33 (1H, s, H-9)

Example 11

5-Ethyl-8-isopropyl-11-hydroxyimino-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one (Compound C48)

[0129] 5-Ethyl-8-isopropyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10,11-dione (300 mg, 0.95 mmol) was dissolved in a solution of hydroxylamine hydrochloride (525 mg, 7.6 mmol) and triethylamine (0.5 mL) in 20 mL of ethanol. The solution was refluxed overnight and then concentrated dryness. The residue was diluted with water and extracted with chloroform twice. The combined organic layers were washed with saturated sodium chloride solution, dried with sodium sulfate followed by evaporation to remove the solvent. The title compound was obtained by subjecting the resulting residue to silica gel-chromatography (chloroform:actone=20:1) and then to crystallization from diethyl ether. 1H-NMR (CDCl3) δ 1.32 (6H, d, CH(CH3)2, 1.73 (3H, t, NCH2CH3), 3.03 (1H, septet, CH), 4.79 (2H, q, NCH2), 7.41-8.00 (6H, m, Ar—H), 8.25 (1H, s, H-9), 15.31 (1H, s, N═OH)

Example 12

5-Ethyl-8-isopropyl-11-hydroxy-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one (Compound C43)

[0130] To an ethanolic solution of 5-ethyl-8-isopropyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10,11-dione (500 mg, 1,58 mmol) was added sodium borohydride (62 mg, 1.64 mmol) in portions followed by stirring at room temperature for 1 hour. After removing ethanol, the reaction mixture was diluted with water and extracted with chloroform twice. The combined organic layers were washed with saturated sodium chloride solution and dried with sodium sulfate followed by evaporating to remove chloroform. The title compound was obtained by crystallizing the residue from acetone-diethyl ether mixture. 1H-NMR (CDCl3) δ 1.35 (6H, d, CH(CH3)2), 1.72 (3H, t, NCH2CH3), 3.11 (1H, septet, CH), 4.79 (2H, q, NCH2), 5.86 (1H, s, H-11), 7.52-7.63 (3H, m, Ar—H), 7.85 (1H, dd, H-9)

Example 13

5-Ethyl-8-isopropyl-11-hydroxy-11-phenyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one (Compound C45)

[0131] 2M solution of phenyl magnesium bromide in THF (1.07 mL, 1.87 mmol) was dissolved in anhydrous methylene chloride. To this solution was added dropwise a solution of 5-ethyl-8-isopropyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10,11-dione (500 mg, 1.58 mmol) in anhydrous methylene chloride with ice cooling and stirring followed by stirring at room temperature overnight. The reaction mixture was treated with 10% hydrochloric acid. The organic layer was separated, washed sequentially with diluted hydrochloric acid and saturated sodium chloride solution and dried with sodium sulfate followed by evaporation to remove methylene chloride. The title compound was isolated by subjecting the residue to silica gel-chromatography (chloroform) and crystallization from diethyl ether. 1H-NMR (CDCl3) δ 1.30 (6H, d, CH(CH3)2), 1,79 (3H, t, NCH2CH3), 3.05 (1H, septet, CH), 4.81 (2H, q, NCH2), 5.18 (1H, s, H-11), 7.16-7.64 (10H, m, Ar—H), 7.96 (1H, d, H-6), 8.37 (1H, d, H-9)

Example 14

5-Ethyl-8-isopropyl-11-phenyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one (Compound C44)

[0132] To a mixture of trimethylsilyl chloride (0.19 mL, 1.5 mmol), sodium iodide (224 mg, 1.5 mmol) and acetonitrile (61 mg, 1.5 mmol) was added dropwise a solution of 5-ethyl-8-isopropyl-11-hydroxy-11-phenyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one in 1,2-dichloroethane with stirring at room temperature. The mixture was stirred at 50° C. overnight followed by allowing to cool to room temperature. The reaction mixture was treated diluted aqueous solution of sodium sulfite. The separated organic layer was washed with water four times and then with saturated sodium chloride solution followed by drying with sodium sulfate. After removing the solvent, the residue was purified by silica gel-chromatography (chloroform) followed by crystallization from diethyl ether to give the title compound. 1H-NMR (CDCl3) δ 1.30 (6H, d, CH(CH3)2), 1.79 (3H, t, NCH2CH3), 3.05 (1H, septet, CH), 4.81 (2H, q, NCH2), 5.18 (1H, s, H-11), 7.16-7.64 (10H, m, Ar—H), 7.96 (1H, d, H-6), 8.37 (1H, d, H-9)

Example 14

5-Ethyl-8-methoxy-9-methyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10,11-dione (Compound C60)

[0133] Step 1. 3-Methyl-4-methoxynitrobenzene

[0134] A solution of 2-fluoro-5-nitrotoluene (7.0 g, 45 mmol) in anhydrous DMF was added to a 28% methanolic solution of sodium methoxide (10.45 g, 54 mmol) under ice-cooling with stirring. The reaction mixture was stirred at room temperature overnight and then poured into ice water. The resulting precipitate was filtered off and dissolved in diethyl ether. This solution was washed with saturated sodium chloride solution, dried with sodium sulfate and evaporated to dryness to give the desired compound. 1H-NMR (CDCl3) δ 2,27 (3H, s, CH3), 3.94 (3H, s, OCH3), 6.87 (1H, d, H-5), 8.03 (1H, d, H-2), 8.11 (1H, dd, H-6)

[0135] Step 2. 2-Bromo-4-methoxy-5-methylaniline

[0136] To a solution of 3-methyl-4-methoxynitrobenzene(7.59 g, 45 mmol) in ethanol was added-iron powder (35 g), water(5 mL) and concentrated hydrochloric acid (0.4 mL). The mixture was refluxed for 1 hour and then filtered while hot. The filtrate was concentrated to dryness. The residue was dissolved in chloroform. The chloroform solution was dried with sodium sulfated and evaporated to give 3-methyl-4-methoxyaniline (7.59 g). To a solution of this compound (6.17 g, 45 mmol) in acetic acid (55 mL) were added dropwise acetic anhydride (4,4 mL, 46 mmol) at room temperature with stirring and then bromine(2,4 mL, 46 mmol) at 50° C. with stirring. The reaction mixture was stirred at the same temperature for 2 hours and poured into ice-water. The resulting precipitate was filtered off, washed with water and dissolved in ethyl acetate. This solution was washed with saturated sodium chloride solution, dried with sodium sulfate and evaporated to dryness to give 2-bromo-4-methoxy-5-methylacetanilide as a crude product. Crystallization from diethyl ether gave pure product (8.27 g).

[0137] This product was dissolved in ethanol and concentrated hydrochoric acid (26 mL) was added thereto. The mixture was refluxed for 2 hours and then concentrated to dryness. The residue was made weak alkaline with sodium hydroxide. The resulting precipitate was filtered off, washed with water and dried under reduced pressure to give the desired compound. 1H-NMR (CDCl3) δ 2.11 (3H, s, CH3), 3,74 (3H, s, OCH3), 3.74 (2H, m, NH2), 6.61 (1H, d, Ar—H), 6.87 (1H, s, Ar—H)

[0138] Step 3. 5-Methyl-6-methoxy-8-bromoisatoic Anhydride

[0139] The title compound was prepared from 2-bromo-4-methoxy-5-methylaniline via 4-methyl-5-methoxy-7-bromoisatin in a manner analogous to that described in Example 5.

[0140] Step 4. 1-Ethyl-5-methyl-6-methoxyisatoic Anhydride

[0141] 5-methyl-6-methoxy-8-bromoisatoic anhydride (1,39 g, 4.8 mmol) in DMF was hydrogenated in the presence of 5% Pd-C overnight. After filtering, the reaction mixture was concentrated to dryness and dissolved in ethyl acetate. This solution was washed with saturated sodium chloride solution, dried with sodium sulfate and evaporated to dryness to give 5-methyl-6-methoxyisatoic anhydride. Reaction of this compound with ethyl iodide in the presence of sodium hydride gave the title compound.

[0142] Step 5. 5-Ethyl-8-methoxy-9-methyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10,11-dione

[0143] 1-Ethyl-5-methyl-6-methoxyisatoic anhydride was reacted with 1,3-indandione as in Example 10 to give the desired compound. 1H-NMR (CDCl3) δ 1.70 (3H, t, NCH2CH3), 2.83 (3H, s, CH3), 3.88 (3H, s, OCH3), 4.64 (2H, q, NCH2), 7.18-7.69 (6H, m, Ar—H)

Example 15

5-Ethyl-8-isobutoxy-9-methyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10,11-dione (Compound C61)

[0144] To a solution of boron tribromide (0.3 mL, 3,3 mmol) in methylene chloride was added dropwise a solution of 5-ethyl-8-methoxy-9-methyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10,11-dione(325 mg, 1.0 mmol) in methylene chloride under ice cooling with stirring followed by stirring at room temperature overnight. The reaction mixture was poured into a 10% aqueous solution of sodium hydroxide. The aqueous layer was acidified with hydrochloric acid to yield a precipitate. This precipitate was filtered off, washed with water and dried under reduced pressure to give the corresponding 8-hydroxy compound (331 mmg, 100%). This product (331 mg, 1.0 mmol) was dissolved in anhydrous DMF and 60% sodium hydride (48 mg, 1.2 mmol) was added thereto at room teperature with stirring.After stirring for 1 hour, the reaction mixture was allowed to react with isobutyl bromide (0.1 mL, 1.5 mmol) added thereto at 60° C. overnight with stirring. The reaction mixture was concentrated to dryness and the residue was dissolved in chloroform. The chloroform solution was washed with saturated sodium chloride solution, dried with sodium sulfate and evaporated to dryness. The residue was purifie by silida gel-chromatography (chloroform:methanol=30:1) to obtain the desired compound. 1H-NMR (CDCl3) δ 1.08 (6H, d, OCH2CH(CH3)2), 1.67 (3H, t, NCH2CH3), 2.13 (1H, m,OCH2CH(CH3)2), 2.80 (3H, s, CH3), 3.72 (2H, d, OCH2CH(CH3)2), 4.64 (2H, q, NCH2), 7.10-7.63 (6H, m, Ar—H)

Example 16

5-Ethyl-8-isobutoxy-9-methyl-11-hydroxy-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one (Compound C62)

[0145] 5-Ethyl-8-isobutoxy-9-methyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10,11-dione was treated as in Example 12 to give the title compound. 1H-NMR (CDCl3) δ 1.10 (6H, d, OCH2CH(CH3)2), 1.69 (3H, t, NCH2CH3), 2.17 (1H, m,OCH2CH(CH3)2), 3.00 (3H, s, CH3), 3,81 (2H, d, OCH2CH(CH3)2), 4.31 (1H, s, H-11), 4.65 (2H, q, NCH2), 5,80 (1H, s, OH), 7.28-7.74 (6H, m, Ar—H)

[0146] Starting from 5-ethyl-8-isopropyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10,11-dione (Compound C47), the following compound have been prepared using known methodology.

[0147] 5-Ethyl-8-isopropyl-11-methyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one (Compound C40) mp 152-154;

[0148] 5-Ethyl-8-isopropyl-11-amino-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one dihydrochloride (Compound C41), mp 200° C. (decomp);

[0149] 5-Ethyl-8-isoproypl-11-methoxyimino-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one (Compound C49) mp 150° C.

[0150] 5-Ethyl-8-isopropyl-11-acetylamino-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one (Compound C42), mp215° C. (decomp); and

[0151] 5-Ethyl-8-isopropyl-11-methoxy-11-phenyl-5,10-dihydro-11H-indeno[1,2-b]quinolin-10-one, (Compound C46), mp 237-239. 22

Example 17

10-Ethyl-7-isopropyl-2-methyl-5,10-dihydro-4H-thieno[3′,2′:4,5]cyclopenta[1,2-b]quinolin-5-one (Compound D51)

[0152] Step 1. 3-Chloro-1-(5-methyl-2-thienyl)-1-propanone

[0153] To a suspension of anhydrous aluminum chloride (4 g,0.03 mol) in nitrobenzene (10 mL) was added dropwise a solution of 2-methylthiophene (2.0 g, 0.02 mol) and 3-chloropropionyl chloride (3.8 g, 0.20 mol) in nitrobenzene (10 mL). After stirring for 3 hours, the reaction mixture was poured into ice-water (200 mL) containing concentrated hydrochloric acid (20 mL) followed by extraction with diethyl ether. The orgaic layer was sequentially washed with water and saturated sodium chloride solution dried with sodium sulfate and evaporated to remove diethyl ether. The residue was further evaporated under reduced pressure to remove nitrobenzene and purified by silica gel-chromatography (hexane:ethyl acetate=19:1) to give the desired compound (2.5 g, 66.2%). 1H-NMR (CDCl3) δ 2.54 (3H, s, CH3), 3.32 (2H, t, CH2Cl), 3,89 (2H,t,COCH2), 6.81-6.83 (1H, m,H-4), 7.56 (1H, d, H-3)

[0154] Step 2. 2-Methyl-4,5-dihydro-6H-cyclopenta[b]thiophen-6-one

[0155] 3-Chloro-1-(5-methyl-2-thienyl)-1-propanone (2,5 g,13.2 mmol) was heated in concentrated sulfuric acid (20 mL) at 100° C. for 50 minutes with stirring. The reaction mixture was gradually poured into ice-water (200 g) and extracted with diethyl ether. The organic layer was sequnetially washed with water and saturated sodium chloride solution, dried with sodium sulfate and evaporated to dryness. The residue was purified by silica gel-chromatography (chloroform) to give the desired compound. 1H-NMR (CDCl3) δ 2.57 (3H, s, CH3), 2.87-2.97 (4H, m,COCH2CH2), 6.75 (1H, s, H-3)

[0156] Step 3. 10-Ethyl-7-isopropyl-2-methyl-5,10-dihydro-4H-thieno[3′,2′:4,5]cyclopenta[1,2-b]quinolin-5-one

[0157] To a 1.53M solution of n-butyl lithium in hexane (0.47 mL, 0.72 mmol) were added under argon atmosphere TMEDA (0.11 mL, 0.72 mmol) at room temperature and then 2-methyl-4,5-dihydro-6H-cyclopenta[b]thiophen-6-one (0.11 g, 0.72 mmol) in anhydrous THF dropwise with ice cooling and stirring. The reaction mixture was stirred at room temperature for 1 hour and ice-cooled again. To this was added dropwise a solution of 1-ethyl-6-isopropylisatoic anhydride (Example 6, step 1) (0.11 g, 0.48 mmol) in anhydrous THF. The reaction mixture was stirred at room temperature for 2 hours and diluted with saturated aqueous solution of ammonium chloride. The organic layer was concentrated to dryness and the residue was dissolved in ethyl acetate. This solution was washed with saturated sodium chloride solution, dried with sodium sulfate and evaporated again. The residue was subjected to silica gel-chromatography (chloroform: acetone=9:1) and crystallization from diethyl ether to give the title compound. 1H-NMR (CDCl3) δ 1.33 (6H, d, CH(CH3)2), 1.58 (3H, t, CH2CH3), 2.64 (3H, s, CH3), 3.10 (1H, septet, CH), 3,78 (2H, s, H-4), 4,49 (2H, q, NCH2), 6.97 (1H, s, H-3), 7.49 (1H, d, H-9), 7.56 (1H, dd, H-8), 8.45 (1H, d, H-6)

[0158] The following compounds have been synthesized in a manner analogous to that described in Example 17.

[0159] 10-Ethyl-7-isopropyl-5,10-dihydro-4H-thieno[3′,2′: 4,5]cyclopenta[1,2-b]quinolin-5-one (Compound D50), mp 168-169° C.

[0160] 10-Ethyl-7-isopropyl-3-methyl-5,10-dihydro-4H-thieno[3′,2′:4,5]cyclopenta[1,2-b]quinolin-5-one (compound D52), mp 195° C. (decomp); and

[0161] 4-Ethyl-7-isopropyl-1-methyl-4,9-dihydro-10H-pyrrolo[2′,3′:4,5]cyclopenta[1,2-b]quinolin-9-one (Compound D53), mp 91-93° C.

BIOLOGICAL EXAMPLES

[0162] 1. In Vitro Anti-Picornavirus Activity

[0163] Poliovirus type 1 (Polio 1, Sabin), echovirus type 11 (Echo 11, Gregory), coxsackievirus type A7 (CA7), coxsackievirus type B4 (CB4,JVB), human rhinovirus type 1B (HRV 1B, B632), HRV 2 (HGP), and HRV 89 (41617-Gallo) were used. Polio 1, Echo 11, and CA7 were assayed in HeLa-S3 cells with the exception of the CB4, which were assayed in HeLa cells; all numbered HRV serotypes were assayed in HeLa (Ohio strain)cells. Cells were seeded at 2.0×104 cells/well (in Eagle MEM plus 7% fetal bovine serum, growth medium) in 96-well tissue culture plate and were incubated for 24 hr. at 37° C. in a CO2 incubator to form monolayer. The growth medium in the plates was removed and a serial 0.5 log10 dilutions of the test compound in 50 μl maintenance medium (Eagle MEM plus 2% heat-inactivated fetal bovine serum) was added to the wells. Each drug concentration was run in quadruplicate. Immediately after addition of compounds, the cells in 96-well plate were infected with appropriate virus at 300-1,000 plaque forming units (PFU) per well in 50 μl of maintenance medium and were incubated at 33° C. for HRVs or 37° C. for enteroviruses. Uninfected cells and cells that received virus in the absence of compound were included on each plate. The anti-picornavirus activities of the compounds were examined by calorimetric assay based on the cells as monitored by reduction of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) to formazan. After 3-5 days, 20 μl of MTT solution (4 mg/ml) in phosphate buffered saline (PBS) was added to each well, and the incubation was continued for an additional 2.5-4 hr. After incubation, 100 μl of 15% SDS in 0.01 N HCl was added to each well to solubilize the bluish violet crystal of formazan and the plates were incubated at 37° C. for an additional 18 hr. The absorbency of formazan at 600 nm with a reference wave length of 660 nm was measured by a computer-controlled microplate reader. The 50% inhibitory concentration (IC50) by the MTT method was defined as the concentration of compound that protected 50% of the cell monolayer from virus-induced cytopathic effect. The percentage protection was calculated by the following equation: [(AT)v−(Ac) v/(Ac)mock−(Ac)v]×100%, where (AT)v, (Ac)v, (Ac)mock indicate absorbencies of the test sample, the virus-infected control (no compound) and mock-infected control, respectively.

[0164] The cytotoxicity of the compound was determined as described above without inoculation of the virus and expressed as the 50% cytotoxic concentration (CC50), i.e., the concentration required to reduce the viability of untreated cells by 50%. The cells were exposed to various concentrations of the test compounds in the maintenance medium and incubated for 4 days.

[0165] A majority of the compounds of the present invention exhibited anti-picornavirus activities as shown in table IV-VI.

TABLE IV
in vitro Anti-picornavirus activity
	IC50(μg/ml)
Com-
pound	Polio 1	Echo 11	CA7	CB4	HRV1B	HRV2	HRV89
A30	1.0	0.42	1.2	1.8	1.6	0.48	1.0
A32	0.93	0.40	1.9	>3.3	1.0	0.55	0.77
A37	1.1	0.91	3.8	6.7	1.0	0.83	0.54
A60	1.1	0.52	2.5	2.8	0.59	0.52	1.1
A61	0.73	0.40	>4	>4	0.64	0.65	0.38
A78	1.3	1.2	7.1	2.6	5.6	1.7	2.9
A81	0.78	0.52	0.78	2.2	1.7	0.86	0.55
A97	0.54	0.3	2.1	1.4	0.58	0.61	0.14
A98	0.66	0.26	2.9	1.2	0.78	0.42	0.36
A99	0.55	0.20	1.8	1.1	0.63	0.50	0.14
A100	0.57	0.24	4.5	1.4	0.85	0.43	0.20
A122	1.2	0.54	6.9	5.5	0.59	0.43	0.35
A130	0.86	0.32	0.17	>4	0.90	0.65	0.72
A157	0.59	0.27	3.8	4.9	1.0	0.56	1.3
A159	0.51	0.26	2.7	3.0	0.78	0.48	0.73
A160	0.55	0.27	2.7	2.9	0.73	0.45	0.78
A169	4.3	1.1	>50	18	8.2	1.0	5.4
A171	0.52	0.22	1.9	2.0	0.43	0.76	0.39
A179	0.29	0.20	2.4	1.2	0.86	0.87	0.37
A181	0.39	0.24	2.4	1.8	1.6	0.94	0.46
A186	0.67	0.27	3.0	1.2	1.1	>1.7	0.26
A187	0.53	0.21	3.0	0.99	0.71	0.57	0.15
A188	0.31	0.27	1.2	1.1	0.81	0.33	0.25
A190	0.58	0.23	3.2	2.4	2.0	0.57	0.28
A191	0.40	0.19	2.5	1.6	1.3	0.15	0.20
A194	0.58	0.45	1.7	1.3	0.05	0.49	0.18
A196	1.1	0.44	9.7	1.9	5.9	1.8	0.86
A226	0.93	0.33	9.7	>3.3	1.6	0.73	<0.033
A234	0.89	0.25	3.8	2.5	1.0	0.26	0.32
A235	0.72	0.27	2.8	2.9	0.75	0.24	0.35
A237	1.1	0.40	>4	2.9	2.0	0.29	0.46
A258	0.62	0.23	4.9	>1.6	0.62	0.45	0.66
A285	0.69	0.2	3.1	1.9	0.68	0.18	0.46
A286	1.3	0.57	>5	1.4	0.87	0.23	0.61
A296	5.1	1.7	20	17	4.5	2.0	4.8
A303	1.4	0.83	6.5	3.6	1.4	0.97	1.9
A304	0.80	0.35	3.6	1.9	0.76	0.34	0.90
A306	0.83	0.49	2.9	2.1	0.89	0.73	0.88
A307	0.79	0.34	1.9	1.3	0.83	0.39	0.86
A308	0.87	0.31	3.9	1.6	0.81	0.36	0.94
A309	0.76	0.28	3.3	1.5	0.48	0.25	0.58
A311	0.67	0.42	3.3	2.0	1.0	0.53	1.2
A313	0.94	0.35	3.8	3.0	0.90	0.33	0.96
A314	0.60	0.51	1.5	0.82	0.56	0.55	0.38
A315	0.54	0.30	1.2	0.63	0.52	0.28	0.26
A316	0.78	0.39	1.2	1.1	0.56	0.29	0.27
A317	0.81	0.35	2.6	1.1	0.82	0.43	0.40
A318	0.47	0.27	2.0	0.65	0.45	0.38	0.16
A319	2.0	0.81	8.9	9.4	1.5	0.80	2.0
A320	>5	0.15	>5	>5	0.12	0.051	0.051
A321	NT	NT	NT	NT	0.60	0.056	0.066
A322	NT	NT	NT	NT	0.18	0.030	0.034
A323	>2	>2	>2	>2	0.27	0.038	0.011
A324	NT	NT	NT	NT	0.53	0.12	0.046
A325	>2.5	>2.5	>2.5	>2.5	>2.5	0.066	0.022
A326	>2.5	>2.5	>2.5	>2.5	>2.5	0.48	0.067

[0166]

TABLE V-1
in vitro Anti-picornavirus activity
	IC50(μg/ml)
	polio	Echo			HRV	HRV	HRV	HRV	HRV
Compd.	1	11	CA7	CB4	1A	1B	2	14	89
B2	0.58	0.19	3.1	0.97	5.0	0.54	0.15	0.65	0.48
B3	0.72	0.35	2.1	0.82	2.6	0.30	0.54	0.74	0.57
B7	0.42	0.25	1.4	0.52	1.7	0.17	0.36	0.49	0.30
B8	0.19	0.17	0.70	0.60	>1	0.24	0.22	0.40	0.12
B9	0.18	0.18	0.71	0.56	>1	0.25	0.20	0.58	0.21
B10	0.17	0.14	1.4	0.57	1.9	0.25	0.16	0.52	0.33
B11	0.45	0.28	>2	1.6	1.7	0.36	0.34	0.78	0.31
B12	0.39	0.19	2.0	0.63	>2.5	0.25	0.31	0.43	0.31
B15	0.49	0.27	2.2	1.9	>2.5	0.36	0.44	0.84	0.39
B20	0.40	0.28	1.4	0.60	>2.5	0.23	0.19	0.51	0.18
B22	0.54	0.39	1.9	1.3	>5.9	0.44	0.55	0.86	0.36

[0167]

TABLE V-2
in vitro Anti-picornavirus activity
	IC50(μg/ml)
	polio	Echo			HRV	HRV	HRV	HRV	HRV
Compd.	1	11	CA7	CB4	1A	1B	2	14	89
C40	0.54	0.24	>3.3	1.7	>3.3	0.51	0.54	1.1	0.56
C43	1.5	0.54	>5	2.9	>5	1.5	0.67	2.5	0.86
C49	0.52	0.26	9.2	2.3	>10	1.9	1.7	5.5	2.1

[0168]

TABLE V-3
in vitro Anti-picornavirus activity
	IC50(μg/ml)
	polio	Echo			HRV	HRV	HRV	HRV	HRV
Compd.	1	11	CA7	CB4	1A	1B	2	14	89
D50	0.64	0.27	1.9	0.82	2.2	0.25	0.20	1.3	0.41
D51	0.28	0.21	1.1	0.72	3.1	0.59	0.27	0.82	0.35
D52	1.0	0.55	>5	3.0	3.1	0.89	0.86	1.1	0.85
D53	1.8	0.68	>10	>3.3	>10	1.6	0.91	2.3	1.4

[0169]

TABLE VI-1
Cytotoxicity
	CC50(μg/ml)
	Compound	HeLa-S3	HeLa	HeLa(Ohio)
	A30	6.5	6.0	5.8
	A32	>10	9.7	>10
	A37	12	11	11
	A60	7.0	5.3	5.7
	A61	>4	>4	>4
	A78	>8	>8	>8
	A81	7.6	6.5	5.8
	A97	>10	5.1	4.5
	A98	>4	>4	>4
	A99	5.8	5.4	5.7
	A100	>5	>5	>5
	A122	>10	>10	>10
	A130	>4	>4	>4
	A157	>5	>5	>5
	A159	>5	>5	>5
	A160	>5	>5	>5
	A169	>50	>50	>50
	A171	>2.5	>2.5	>2.5
	A179	>4	>4	>4
	A181	>2.5	>2.5	>2.5
	A186	>5	>5	5.0
	A187	>4	>4	>4
	A188	>5	>5	>5
	A190	>4	>4	>4
	A191	>4	>4	>4
	A194	>2.5	>2.5	>2.5
	A196	>10	>10	>10
	A226	>10	>10	>10
	A234	>5	>5	>5
	A235	>4	>4	>4
	A237	>4	>4	>4
	A258	>5	4.5	4.9
	A285	>4	>4	>4
	A286	>5	>5	>5
	A296	>100	75	68
	A303	>20	>20	>20
	A304	>20	18	19
	A306	26	14	25
	A307	>20	>20	18
	A308	16	11	11
	A309	18	12	14
	A311	>10	6.8	>10
	A313	>20	18	15
	A314	>10	7.0	>10
	A315	>10	7.1	>10
	A316	>5	>5	>5
	A317	>5	>5	>5
	A318	>2.5	>2.5	>2.5
	A319	>50	35	32
	A320	>5	>5	>5
	A321	NT	NT	>1
	A322	NT	NT	>1
	A323	>2	>2	>2
	A324	NT	NT	>1
	A325	>2.5	>2.5	>2.5
	A326	>2.5	>2.5	>2.5

[0170]

TABLE VI-2
Cytotoxicity
	CC50(μg/ml)
	Compound	HeLa-S3	HeLa	HeLa(Ohio)
	B2	>10	>10	>10
	B3	>4	>4	>4
	B7	>2.5	>2.5	>2.5
	B8	>1	>1	>1
	B9	>1	>1	>1
	B10	>2.5	>2.5	>2.5
	B11	>2	>2	>2
	B12	>2.5	>2.5	>2.5
	B15	>2.5	>2.5	>2.5
	B20	>2.5	>2.5	>2.5
	B22	>10	>10	>10

[0171]

TABLE VI-3
Cytotoxicity
	CC50(μg/ml)
	Compound	HeLa-S3	HeLa	HeLa(Ohio)
	D50	>10	7.8	>10
	D51	>5	>5	>5
	D52	>5	>5	>5
	D53	>10	>10	>10

[0172] 2. Anti-Rhinovirus Spectrum

[0173] In the above cell-based assays, some compounds demonstrate potent antiviral activities against 3 HRV serotypes tested. Therefore, we expanded our assessment of the antiviral activity of the compounds to a larger panel of HRV serotypes. HRV1A (E28), HRV3(FEB), HRV50, HRV8(MRH), HRV10 (204-CV14), HRV13 (353), HRV14 (1059), HRV16 (11757), HRV21 (47), HRV29 (5582), HRV31 (41F), HRV32 (363), HRV33 (1200) HRV36 (342H), HRV39 (209), HRV41 (56110), HRV50(A2#58), HRV61 (6669-CV39), and clinical isolate (89229T) were tested in the same method described above for sensitivity to the compounds. As shown in Table VII and VIII, some of the compounds exhibit potent activity against a broad spectrum of rhinovirus serotypes.

TABLE VII
Anti-rhinovirus activity
Rhinovirus
Serotype	Compd. A320	Compd. A322	Compd. A323
HRV1A	>5.0	>1.0	>2.0
HRV1B	0.12	0.18	0.27
HRV2	0.051	0.030	0.038
HRV3	>5.0	>1.0	>2.0
HRV5	>5.0	>1.0	>2.0
HRV8	>5.0	>1.0	>2.0
HRV10	0.021	0.013	0.032
HRV13	0.23	0.029	0.12
HRV14	>5.0	>1.0	>2.0
HRV16	0.023	0.030	0.033
HRV21	0.024	0.048	0.067
HRV29	0.079	0.080	0.11
HRV31	0.046	0.045	0.088
HRV32	0.051	0.020	0.077
HRV33	0.23	0.17	0.30
HRV36	0.082	0.085	0.13
HRV39	<0.017	0.012	0.018
HRV41	0.066	0.034	0.058
HRV50	0.020	0.023	0.038
HRV61	0.21	0.29	0.30
HRV89	0.051	0.034	0.011
Clinically	0.017	0.017	0.030
isolated
strain

[0174]

TABLE VIII
Anti-Rhinovirus activity
		Compd.	Compd.	Compd.	Compd.	Compd.	Compd.	Compd.
Virus	Compd. B3	B7	B9	B10	B12	B15	B20	B22
HRV1A	2.6	1.7	>1.0	1.9	>2.5	>2.5	>2.5	>5.9
HRV1B	0.30	0.20	0.25	0.25	0.25	0.36	0.23	0.44
HRV2	0.54	0.36	0.20	0.16	0.31	0.44	0.19	0.50
HRV3	2.9	0.49	0.23	0.48	0.52	1.1	0.50	0.97
HRV5	0.36	0.22	0.17	0.24	0.29	0.39	0.23	0.43
HRV8	0.46	0.32	0.15	0.20	0.32	0.38	0.29	0.46
HRV10	1.8	0.41	0.47	0.41	0.43	1.1	0.42	0.53
HRV13	0.17	0.13	0.14	0.12	0.091	0.18	0.13	0.13
HRV14	0.74	0.49	0.58	0.52	0.43	0.84	0.51	0.86
HRV16	2.3	0.98	0.47	0.57	1.4	1.2	0.44	1.2
HRV21	0.20	0.11	0.16	0.16	0.17	0.34	0.14	0.18
HRV29	1.5	0.43	0.19	0.44	0.44	0.67	0.44	0.56
HRV31	0.29	0.13	0.15	0.15	0.11	0.38	0.18	0.14
HRV32	0.61	0.30	0.13	0.36	0.33	0.65	0.29	0.19
HRV33	0.20	0.097	0.094	0.11	0.12	0.29	0.097	0.16
HRV36	0.30	0.16	0.16	0.17	0.21	0.32	0.20	0.25
HRV39	1.7	0.38	0.20	0.39	0.38	0.46	0.35	0.46
HRV41	0.20	0.064	0.13	0.007	0.11	0.18	0.12	0.14
HRV50	0.20	0.12	0.13	0.10	0.12	0.28	0.18	0.17
HRV61	0.80	0.28	0.16	0.24	0.31	0.39	0.31	0.34
HRV89	0.57	0.30	0.21	0.33	0.31	0.39	0.18	0.36
Clinical	1.9	0.50	0.31	0.75	0.46	1.1	0.49	0.43
isolated
strain

[0175] 3. In Vitro Anti-Rotavirus Activity

[0176] Human rotavirus (HROV, Odelia) and simian rotavirus (SRoV, SA11) were used in this experiment. Confluent monolayers of MA104 cells in 6-well multiplate were washed with Eagle MEM containing 0.5 μg/ml of trypsin and were infected with tripsinized-rotavirus (treated with 10 μg/ml of tripsin at 37° C. for 1.5 hr) at 50 PFU per well. After 1 hr of adsorption, the virus inoculum was removed, and the monolayers were washed with Eagle MEM containing 0.5 μg/ml of trypsin and overlaid with Eagle MEM containing 1 μg/ml of trypsin, 0.6% purified agar and the test compounds at various concentrations. The cultures were incubated at 37° C. for 3 days and same overlay medium was added. Four days after infection, the cell sheets were washed with PBS and stained with 1.3% crystal violet in 95% ethanol. The antiviral efficacy of the compounds was expressed as the IC50, that is the concentration of the compounds required to reduce the number of plaques to 50% in the control (virus-infected, but not untreated).

[0177] The compounds tested specifically inhibited the multiplication of HRoV (Odelie) and SRoV (SA11) as shown in Table IX.

TABLE IX
Anti-rotavirus activity
	IC50(μg/mL)
	Compound	HRoV(Odelia)	SRoV(SA11)
	A323	1.30	0.90
	B9	0.56	0.59

Claims

1. A 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compound of Formula I:

2. A compound according to claim 1 of Formula I-a:

3. A compund according to claim 1 of Formula I-b:

4. A compound according to claim 1 of Formula I-c:

5. A compound according to claim 1 of Fomula I-d:

6. A compound according to claim 1 of Formula I-c:

7. A compound according to claim 1 of Formula I-f:

8. A compound according to claim 1 of Formula I-g

9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition according to claim 9 for use in the prophylaxis and the treatment of Picornavirus and human rotavirus infections.